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ABSTRACT
Heme is the major iron source for the deadly human pathogen, Group A Streptococcus (GAS).
During infection, GAS lyses host cells releasing hemoglobin and other hemoproteins. This
dissertation aims to elucidate the general mechanism by which GAS obtains and utilizes heme as
an iron source from the host hemoproteins. GAS encodes a heme relay system consisting of Shr,
Shp and the SiaABC transporter. We specifically determine the role of Shr in the heme uptake
process, by conducting a detailed functional characterization of its constituent domains. We also
undertake to solve the long-standing mystery surrounding the catabolism of heme in
streptococci. The studies presented herein established Shr as a prototype of a new family of
NEAT-containing hemoproteins receptors. They demonstrate its importance in heme acquisition

by GAS and provide a molecular model for heme scavenging and transfer by the protein. We
show that Shr modulates heme uptake depending on heme availability by a mechanism where
NEAT1 facilitates fast heme scavenging and delivery to Shp, whereas NEAT2 serves as a
temporary storage for heme on the bacterial surface. Finally, we identified and characterized for
the first time, a heme oxygenase (HO) in the Streptococcus genus which was named HupZ.
Sequence comparison between HupZ and several HOs from different structural families indicates
that this enzyme is unrelated to any of the previously characterized HOs. However, orthologs of
the protein are found in other important pathogens. The structure and the catalytic mechanism of
HupZ suggest that it is the representative of a new family of flavoenzymes capable of degrading
heme using their reduced flavin cofactor as a source of electrons. Overall, this work contributes
significant knowledge to the topic of heme utilization by pathogens and importantly, provides
new direct evidence that associates flavins with heme metabolism in bacteria. Thus it sets a new
direction in the field and lays the ground for future fundamental and applied discoveries.

INDEX WORDS: Heme acquisition, Heme transfer, Shr, Hemoglobin, Hemoprotein, Kinetics,
Protein-protein interaction, Structure/Function, Heme oxygenase, Biliverdin, Bilirubin,
Streptococcus pyogenes, Iron, UV-visible spectroscopy, Stopped-flow, ELISA

MOLECULAR MECHANISM OF HEME ACQUISITION AND DEGRADATION BY THE
HUMAN PATHOGEN GROUP A STREPTOCOCCUS

by

MAHAMOUDOU OUATTARA

A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy
in the College of Arts and Sciences
Georgia State University
2013

Copyright by
Mahamoudou Ouattara
2013

MOLECULAR MECHANISM OF HEME ACQUISITION AND DEGRADATION BY THE
HUMAN PATHOGEN GROUP A STREPTOCOCCUS

by

MAHAMOUDOU OUATTARA

Committee Chair: Dr. Zehava Eichenbaum

Committee: Dr. Parjit Kaur
Dr. Chang-Dar Lu
Dr. Adam Wilson

Electronic Version Approved:

Office of Graduate Studies
College of Arts and Sciences
Georgia State University
May 2013

iv

DEDICATION

To my parents and to everyone who directly or indirectly contributed to my education.

“And because all things have contributed to your advancement,
You should include all things in your gratitude.”
Wallace D. Wattles

v

ACKNOWLEDGEMENTS
I express my sincere gratitude to my advisor and mentor Dr. Zehava Eichenbaum for
everything and especially for welcoming me in her lab. She is a great person, an excellent
scientist, and a wonderful mentor. Her unique mentoring style allowed for creative and
independent thinking, while providing great guidance and suggestions. The joyful and friendly
working environment in the Eichenbaum lab was created and maintained by the combined efforts
of all previous and current lab members. Thank you all for your collaboration and for being good
colleagues and friends. I am very thankful to our collaborators that have contributed to this work.
In particular, Dr. Dabney Dixon and her lab for helping me understand heme Chemistry, Dr.
Giovanni Gadda for allowing us to conduct the stopped-flow experiments. All the kinetic studies
were carried out with Dr. Andrea Pennati in Dr. Gadda’s lab. I also thank Gadda’s lab members
for sharing the instruments and for being always helpful. I am thankful to Dr. Irene Weber and to
her lab, for helping solve the crystal structure of HupZ. I address a special thanks to Dr. Eric
Gilbert for giving me my first research opportunity at GSU, for his kindness, his promptitude to
help and for recommending me to Dr. Eichenbaum. I also thank Dr. Gilbert’s previous and
current lab members, whom I very much enjoyed working with. I thank my committee mebers,
Dr. Parjit Kaur, Dr. Chang-Dar Lu and Dr. Adam Wilson, for their advices, suggestions and for
the enjoyable committee meetings. Many thanks to the department of Biology, all of the
administrative staff and the Biology core facility. I am grateful to the Molecular Basis of
Diseases fellowship program for the financial support. I express my heartfelt thanks to my
wonderful wife, for her love and support. Finally, I thank my family for its constant
encouragement and support in everything I undertake.

vi

TABLE OF CONTENTS

ACKNOWLEDGEMENTS ................................................................................................ ….. ..v
LIST OF TABLES ....................................................................................................................... ix
LIST OF FIGURES ...................................................................................................................... x
GENERAL INTRODUCTION………………………………………………………………….1
Group A Streptococcus (GAS)…………………………………………………………..1
Heme uptake by bacteria………………………………………………………………...3
The Sia system……………………………………………………………………………5
Heme oxygenases…………………………………………………………………………6
Research objectives and significance…………………………………………………...9
CHAPTER I: SHR OF GROUP A STREPTOCOCCUS IS A NEW TYPE OF
COMPOSITE NEAT PROTEIN INVOLVED IN SEQUESTERING HAEM FROM
METHEMOGLOBIN…………………......................................................................................11
Introduction 1…………………………………………………………………………..11
Results 1………………………………………………………………………………...15
Discussion 1…………………………………………………………………………….27
Materials and Methods 1………………………………………………………………34
CHAPTER II: MECHANISMS OF INTRA- AND INTER-MOLECULAR HEME
TRANSFER BY THE SHR PROTEIN OF GROUP A
STREPTOCOCCUS……………………………………………………………………………44
Introduction 2…………………………………………………………………………..44
Results 2………………………………………………………………………………...47

Discussion 2…………………………………………………………………………….55
Materials and Methods 2………………………………………………………………62
CHAPTER III: DISCOVERY OF HUPZ, THE FIRST STREPTOCOCCAL HEME
OXYGENASE…………………………………………………………………………………..68
Introduction 3…………………………………………………………………………..68
Results 3………………………………………………………………………………...71
Discussion 3…………………………………………………………………………….77
Materials and Methods 3………………………………………………………………80
GENERAL DISCUSSION……………………………………………………………………..84
The novel Hb binding motif in Shr NTD………………………………………...........84
Significance of heme reduction by Shr…………………………………………...........85
Basis for the heme degradation by HupZ alone………………………………………86
Potential in vivo reducing partners of HupZ………………………………………….88
HupZ heme degradation products…………………………………………………….89
REFERENCES.............................................................................................................. ………135

ix

LIST OF TABLES

Table 1: Primers used in Chapter 1…………………………………………………………...42
Table 2. Plasmids used in Chapter 1 ......................................................................................... 43
Table 3: Strains and Plasmids used in Chapter 2…………………………………………….66
Table 4: Primers used in Chapter 2…………………………………………………………...67
Table 5: Strains and Plasmids used in Chapter 3…………………………………………….83
Table 6: Primers used in Chapter 3…………………………………………………………...83

x

LIST OF FIGURES
Figure 1: Schematic representation of the sia operon and the Shr protein and Heme relay
in Group A Streptococcus……………………………………………………………………...92
Figure 2: Catalytic mechanism of heme oxygenases………………………………………….93
Figure 3: Shr proteins in pyogenic Streptococci and Clostridium novyi…....……………….95
Figure 4: Hemin binding and reduction by rShr……………………………………………..95
Figure 5: Heme binding by Shr fragments……………………………………………………97
Figure 6: Methemoglobin binding by Shr fragments………………………………………..99
Figure 7: Binding of extracellular matrix proteins by Shr…………………………………100
Figure 8: Heme transfer from methemoglobin to apoNTD-N1…………………………….101
Figure 9: Growth analysis of shr deletion mutants………………………………………….102
Figure 10: Heme acquisition from MetHb…………………………………………………..104
Figure 11: Kinetics of heme transfer from metHb to apoNTD-N1………………………...105
Figure 12: Kinetics of heme transfer from metHb to the full-length Shr………………….106
Figure 13: Kinetics of heme transfer from Shr NEAT domains to apoShp……………….107
Figure 14: Heme transfer from holoNEAT1 to apoNEAT2………………………………...108
Figure 15: Proposed model of heme acquisition by the S. pyogenes Sia system…………..109
Figure 16: Heme binding by HupZ…………………………………………………………..110
Figure 17: Heme degradation by HupZ without external electron donors………………..111
Figure 18: heme degradation by HupZ using CPR-NADPH as reducing equivalent…….112
Figure 19: heme degradation by HupZ with ascorbic acid as a source of electrons……...113
Figure 20: Phylogenetic tree of bacterial heme oxygenases generated from ClustalW2
(EMBL-EBI)…………………………………………………………………………………...113

xi

Figure S1: NEAT alignment………………………………………………………………….114
Figure S2: UV-visible spectra of hemin chloride……………………………………………115
Figure S3: Heme reconstitution of NEAT2 protein fragment……………………………...115
Figure S4: Binding of rShr to holo and apo hemoglobin…………………………………...116
Figure S5: Heme transfer from methemoglobin to apoNTD-N1.…………………………..117
Figure S6: Growth phenotype of wild type GAS and Shr mutants………………………...118
Figure S7: Recombinant His-MBP-NEAT1 and Shp-His proteins………………………...119
Figure S8: Western blot analysis with anti-Hb antibodies of Shr elution fractions………120
Figure S9: Heme reconstitution spectra of MBP-NEAT1 and MBP………………………121
Figure S10: MetHb binding by Shr fragments……………………………………………...122
Figure S11: Heme transfer from metHb to Shr fragments…………………………………123
Figure S12: Comparative spectra of NTD-N1 and metHb………………………………….124
Figure S13: Spectral differences between metHb and NTD-metHb complex……………..125
Figure S14: Gel filtration elution profiles of NTD-N1 and aldolase……………………….126
Figure S15: The observed rate constants for the third phase of heme transfer from metHb
to Shr…………………………………………………………………………………………...128
Figure S16: UV-visible spectrum of purified holoShp……………………………………...129
Figure S17: SDS-PAGE analysis of NEAT2 elution fraction after incubation with
NEAT1…………………………………………………………………………………………130
Figure S18: characterization of the purified recombinant HupZ………………………….131
Figure S19: UV-visible absorbance spectra of heme bound HupZ and of the heme-pyridine
adduct…………………………………………………………………………………………..132

xii

Figure

S20:

Characteristic

color

of

HupZ-CPR-NADPH

heme

degradation

reaction………………………………………………………………………………………....132

1

GENERAL INTRODUCTION

Group A Streptococcus (GAS)
Also known as Streptococcus pyogenes, GAS is a Gram-positive coccus that grows in
chains of variable lengths. When grown on blood agar, the bacterium produces hemolysins,
which achieve complete lysis of red blood cells. This is known as β-hemolysis and results in
clearing zones around the bacterial colonies. GAS is an important human pathogen that causes a
large number of diseases with different clinical manifestations. Repeated GAS infections can
also lead to severe immune sequelae such as acute glomerulonephritis and rheumatic fever [1-3].
Cases of non-invasive infections caused by the bacterium worldwide are estimated at 700 million
each year. Of these, about 650,000 progress to serious invasive infections resulting in about 25%
mortality [1]. Invasive GAS infections often require substantial treatments including surgical
procedures. To date no approved commercial vaccine is available against streptococcal infections
[4,5]. The emm gene encodes the antigenically variable surface M-protein, which serves as a
basis for GAS classification into serotypes. More than 100 M-types have been identified [2,6].
The most common disease caused by GAS is pharyngitis or “strep-throat”. It is often
associated with symptoms such as sore throat, enlarged and tender lymph nodes in the neck,
headache, fever, malaise and sometimes abdominal pain. Several rapid tests based on bacterial
surface determinants or throat cultures are used to diagnose GAS infections [2]. Penicillin is the
preferred drug for the treatment of GAS pharyngitis, but alternative antibiotics such as
amoxicillin, erythromycin or oral cephalosporins are used in case of allergy to penicillin. Other
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non-invasive GAS illnesses include the skin infections impetigo and cellulitis, and the acute
inflammation of the skin and superficial lymphatic vessels erysipelas [7]. Non-invasive GAS
diseases can progress to life-threatening invasive infections, which may also occur as a result of
a direct inoculation due to penetrating injuries. One of the most severe invasive GAS infections
is the streptococcal gangrene or necrotizing fasciitis, also known as “flesh-eating disease”. The
common clinical manifestations of the disease are severe pain at the site of infection even
without an obvious sign of skin break, swelling, fever, confusion, stretched and discolored
overlying skin. Successful treatment of necrotizing fasciitis dependents on the early diagnosis of
the illness and requires timely and intense surgical procedures in conjunction with antimicrobial
treatments [7,8].
GAS owes its ability to cause a wide variety of diseases to a multitude of virulence
factors. Few examples include the M-protein, which mediates the attachment of the bacteria to
host’s epithelial cells and participates in the bacteria resistance to opsonophagocytosis. Escaping
phagocytosis is accomplished through binding of molecules such as fibrinogen, C4b-binding
protein, immunoglobulin Fc portion and the H factor, which inhibits the complement system [911]. A capsule composed of hyaluronic acid, a normal component of human tissue, surrounds
invasive GAS strains allowing them to escape the host immune response [12,13]. The
streptococcal pyrogenic exotoxins (SPEs) are superantigens that can trigger massive uncontrolled
release of cytokines and lead to septic shock. Several enzymes produced by GAS also facilitate
the breaking down of DNA, blood clots and proteins including immunoglobulins. GAS exotoxins
streptolysins O and S produce pores in the membrane of leukocytes and erythrocytes, causing
their lysis and the release of hemoglobin which can serve as a nutrient to the pathogen [14-17].
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Heme uptake by bacteria
Iron is an essential micronutrient for nearly all living systems including bacteria. In many
enzymes, iron is a catalytic center involved in redox reactions, which carry out vital cellular
processes. These include electron transport, DNA and amino acids synthesis, photosynthesis,
activation of oxygen and peroxide reduction. Iron is one of the most abundant elements on earth
and exists mainly in the oxidized ferric (Fe3+) or the reduced ferrous (Fe2+) forms. Fe3+ is highly
insoluble and represents the most predominant iron species in aerobic and neutral pH conditions.
In contrast, Fe2+ is more soluble but is present only in a limited number of anoxic and strongly
acidic habitats. Therefore, in spite of its abundance, iron is biologically unavailable in the
environments inhabited by the vast majority of microorganisms [18-20].
In mammalian hosts, bacteria are also confronted with iron-restricted environments,
where free iron is sequestered in extracellular (transferrin, lactoferrin) and intracellular (ferritin)
host proteins with high affinity for the metal. However, the most abundant source of iron in
mammals consists of heme, an iron-protoporphyrin IX molecule. It is a hydrophobic tetrapyrrole
with an iron center that can partition into membranes, thus impairing lipid bilayers. Free heme
also induces non-enzymatic redox reactions which generate toxic amounts of reactive radicals
causing severe cell damage [21]. Because of its toxicity, only minute amount of free heme is
allowed intracellularly or in the blood. The large majority of heme is sequestered by host
proteins, mainly hemoglobin (Hb), a tetrameric protein with two α- and two β-chains. Each
subunit of the tetramer binds one heme molecule. Hb is confined in erythrocytes where it serves
as the oxygen transporter in its reduced form, oxyhemoglobin. When released from the red blood
cells, the tetrameric Hb spontaneously oxidizes to the dimeric methemoglobin (metHb) [22].
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The total blood Hb concentration in healthy human adult is estimated between 1.9 and 2.3 mM,
suggesting a relative abundance [23]. Though, it remains highly unavailable to pathogens, as free
extracellular Hb is readily scavenged by the serum protein, haptoglobin [24].
To survive the hostile iron-restricted conditions they face during infection, pathogens
evolved sophisticated machineries to scavenge and import heme from host hemoproteins that are
released upon hemolysis and tissue damage. Strategies used by many Gram-negative pathogens
involve hemophores, which are extracellular bacterial proteins secreted in the environment to
bind free heme or to scavenge heme from host proteins. The heme-bound hemophore
subsequently recognizes and delivers its heme to a specific receptor at the cell surface, leading to
heme import inside the cell [20,25]. Examples of hemophore-mediated heme uptake mechanisms
are described in Gram-negative pathogens Serratia marcescens, Pseudomonas aeruginosa,
Yersinia enterocolitica and Hemophilus influenza [26-31]. Some Gram-negative organisms also
rely on outer-membrane receptors for heme acquisition. Examples include HmbR and HpuA in
Neisseria species, ChuA in E. coli and HutA in Vibrio cholerae [32-36].
The predominant heme uptake mechanism adopted by Gram-positive organisms uses a
protein relay. Heme is obtained from host molecules by a surface receptor, then transferred in a
cascade manner through the thick peptidoglycan layers to a cognate ABC transporter, which
carries it across the cytoplasmic membrane [37,38]. Heme capture and transfer by surface
receptors are in the vast majority of cases mediated by a protein domain referred to as NEAT
(NEAr-iron Transporter). This protein module is encoded in a variable copy number in the
genome of several Gram-positives, in close vicinity of iron ABC transporters. NEAT domains
are approximately 125 amino acids long, sharing low primary sequence homology and a
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predicted secondary structure of mostly β-strands [39]. Heme acquisition systems that employ
NEAT-containing receptors are widely studied in Staphylococcus aureus, Bacillus species and
Listeria monocytogenes [37-39]. In addition to these surface receptors, secreted NEAThemophores are also found in Gram-positives. Some examples are illustrated by IsdX1 and
IsdX2 in Bacillus anthracis [40,41]. Recently, heme relays which do not involve NEATcontaining receptors were reported in Corynebacterium diphteriae and Mycobacterium
tuberculosis [42,43].

The Sia system
GAS utilizes heme and host hemoproteins as iron source during infection [44]. The two
known heme acquisition pathways in GAS involve of the streptococcal iron uptake (siu) and the
streptococcal iron acquisition (sia) systems [45,46]. The sia system consists of a conserved tengene operon which is directly repressed by the iron-dependent regulator MtsR [45,47] (fig. 1A).
The first gene in the operon encodes Shr (streptococcal hemoproteins receptor), a 145 kDa
composite surface protein. Shr contains two NEAT domains, a series of leucin-rich repeats
located between the NEAT domains and a unique N-terminus region (NTD) with two copies of a
domain of unknown function (DUF1533). Shr C-terminus has a hydrophobic region with a
positively charged tail that allows the attachment of the protein to the cytoplasmic membrane.
Unlike other NEAT-containing receptors, Shr does not contain a cell wall-anchoring motif, but is
exposed to the extracellular environment by protruding through the cell wall. The protein binds a
wide range of ligands such as heme, Hb, Hb-haptoglobin complex and the extracellular matrix
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(ECM) proteins fibronectin and laminin [45,48]. Shr does not share significant homology to any
characterized heme or hemoprotein receptor and its composition and overall domain architecture
are unique (fig. 1A). The second gene in the sia locus codes for the heme-binding surface protein
Shp (streptococcal hemoprotein), which has a NEAT-like domain considered as remotely related
to the NEAT family [49,50]. The third, fourth and fifth genes of the sia operon express a heme
ABC transporter (SiaABC or HtsABC) where SiaA serves as the heme ligand-binding
lipoprotein component. Heme coordination in SiaA is mediated by a set of two different axial
ligands which were recently identified as Met79 and His229 [51,52]. These two residues also
participate in the release of heme from SiaA in a two-step process that involves a conformational
change of the protein [52]. From Shr, heme is efficiently transferred to Shp, which in turn gives
it to SiaABC where it is carried across the cytoplasmic membrane [53,54] (fig. 1B). The function
of the proteins encoded by the remaining genes of the operon is unknown. The importance of
heme uptake in GAS virulence was demonstrated in zebrafish and mouse models [46,48,55].
While Shr is proposed to participate in heme acquisition, its direct role in the scavenging and
transfer of heme from hemoproteins to Shp has not been established. In addition, the function
and importance of the receptor domains are yet to be studied.

Heme oxygenases
Heme imported into the bacterial cytoplasm is incorporated to intracellular proteins as a
cofactor, or utilized by the organism as an iron source. In the latter case, the release of iron from
the porphyrin ring requires the activity of enzymes such as deferrochelatases [56] or heme
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oxygenases (HO) [57]. However, the mode of action of deferrochelatases in iron release from
heme is controversial, as contradictory data are provided by different studies [58]. HOs catalyze
the oxidative cleavage of the methene (meso) carbon bridges of the porphyrin at the positions α,
β, γ or δ [59]. There are three known mammalian HOs: the inducible HO-1 [60], the constitutive
HO-2 [60] and HO-3 whose functional relevance is unknown [61]. HO-1 is highly induced by
chemical agents and a variety of stress conditions and is found in highest concentration in the
spleen and liver. HO-2 is unresponsive to exogenous stimuli and is preponderant in the brain and
testes [60]. The two isoforms participate in many physiological processes such as
neuroprotective activities, iron homeostasis, protection from heme toxicity and oxidative stress
[60,62-65].
Heme degradation by HOs requires a source of reducing equivalents, which is provided
in mammals by NADPH and cytochrome P450 reductase (CPR). The reaction typically results
in equimolar quantities of iron, carbon monoxide (CO) and biliverdin (fig. 2). The heme
catabolite, biliverdin is further converted to bilirubin by biliverdin reductase [60,66]. Each of the
heme degradation products participates in a number of physiological processes. Iron for example,
is necessary for erythropoiesis and participates in oxygen transport. Biliverdin and bilirubin are
powerful antioxidants and CO is a vasodilator that is believed to regulate adequate blood flow
[63,67-70]. CO is also a signaling molecule that modulates many physiological processes. It was
shown to be important for the neovascularization during wound healing and it stimulates the
proliferation of endothelial cells. Moreover, CO has been recognized as a neurotransmitter, an
immunomodulator and an anti-inflammatory agent [71].
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Homologues of the human HO-1 are found in bacteria. The first example of bacterial HO,
named HmuO, was identified and characterized in the pathogen Corynebacterium diphteriae
[72,73]. Ever since, several other bacterial HOs that share sequence homology with HmuO were
identified. These include HemO in Neisseria meningitides and Clostridium species, PigA (also
known as pa-HO) and BphO in Pseudomonas aeruginosa [74-78]. Structurally, this group of
enzymes consists of monomeric α-helices with similar folds. They specifically degrade heme at
the α-meso carbon, producing α-biliverdin [66]. The only exception in this group is PigA which
has an unusual β-meso and δ-meso regiospecificity, producing a mixture of β- and δ-biliverdins
[77]. The fate of the biliverdin produced in bacterial cell is unknown in most cases, since a
homologue of mammalian biliverdin reductase has been identified only in cyanobacteria [79,80].
Two bacterial HOs, IsdG and IsdI, distinct in structure from the mammalian HO-1 were
found in Staphylococcus aureus. These enzymes are part of the isd locus which also encodes the
NEAT-containing hemoprotein receptors and their cognate ABC transporter. IsdG and IsdI are βbarrel homodimers containing two active sites and catalyze the formation of the atypical product,
staphylobilin. This contrasts with the canonical production of biliverdin [81-83]. Homologues of
IsdG with similar structural and biochemical features were characterized in Bradirhyzobium
japonicum, Mycobacterium tuberculosis, Bacillus anthracis and Staphylococcus lugdunensis
[84-87]. Additional heme degrading enzymes which do not resemble HO-1 or IsdG-like groups
of proteins were also described. ChuS in Escherischia coli has a unique structure consisting of
two central sets of antiparallel β-sheets, each flanked by two pairs of α-helices [88]. Heme
degradation by ChuS in presence of reducing partners produced CO and spectral features that
suggest biliverdin production. However, the final products of the reaction were not identified
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[88]. HemS, a protein with high sequence homology to ChuS was uncovered in Yersinia
enterocolitica and Bartonella henselae [89,90]. Like ChuS, the products of HemS-catalyzed
reaction are undefined [90].
A new family of bacterial HOs with no sequence or structural homologies to previously
described groups of HOs has been emerging recently. Members of this class of enzymes include
Cj1613c in Campylobacter jejuni, HugZ in Helicobacter pylori and HutZ in Vibrio cholerae [9193]. These enzymes share weak sequence similarities with FMN-binding proteins and exist as
dimers [92-95]. The crystal structures of HugZ and HutZ are almost identical besides a mismatch
of one amino acid residue in β6 of HutZ. Both proteins adopt a split β-barrel fold which
characterizes FMN-binding proteins, but actual FMN binding by these proteins was not
demonstrated [94,95]. Similar to PigA, HugZ cleaves the heme tetrapyrrole at the δ-meso carbon,
producing δ-biliverdin and HutZ is hypothesized to produce both β- and δ-biliverdin [92,93].
In GAS and all other streptococci, the mechanism by which iron is released from heme is
unknown. Homologues belonging to the families of the HOs described above have not been
identified in the Streptococus genus.

Research objectives and significance
The purpose of this dissertation is to elucidate the general mechanism by which GAS
obtains and utilizes heme as an iron source from the host hemoproteins. We specifically
determine the role of Shr in the heme uptake process by conducting a detailed functional
characterization of the constituent domains of the protein. We also undertake to conduct a
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comprehensive kinetic study to establish the intra- and inter-molecular flow of heme in the
streptococcal system. Moreover, we aimed to solve the long-standing mystery surrounding the
catabolism of heme in streptococci.
The studies presented herein establish Shr as a prototype of a new family of NEATcontaining hemoproteins receptor. They demonstrate the importance of Shr in heme acquisition
by GAS and provide a molecular model for heme scavenging and transfer by the protein. This
work also brings to light a unique mechanism for the modulation of the heme acquisition
process. We have identified and begun characterizing the first heme oxygenase in GAS. This
new enzyme seems to represent a novel HO expressed by several streptococcal pathogens.
Overall, this dissertation adds a significant knowledge to the blooming topic of heme utilization
as an iron source by pathogens and lays the ground for future fundamental and applied
discoveries.
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CHAPTER I

SHR OF GROUP A STREPTOCOCCUS IS A NEW TYPE OF COMPOSITE NEAT
PROTEIN INVOLVED IN SEQUESTERING HAEM FROM METHEMOGLOBIN

Introduction 1

Acquisition of iron from host sources is of vital importance to many pathogenic bacteria
during the course of infection. Mammalian hosts limit the availability of free extracellular iron
to levels around 10-18 M [96] by producing iron-chelating proteins such as lactoferrin and
transferrin or by storing it in ferritin within the cells. However, nearly 75% of the iron in the
human body is found in the form of heme, where it is incorporated into the protoporphyrin ring
and serves as a prosthetic group of hemoglobin, myoglobin, and some enzymes [97,98]. The
process of obtaining heme from the host by Gram-positive pathogens often involves binding of
heme or hemoproteins by bacterial receptor proteins which then deliver the heme to a membranebound ABC transporter for translocation to the cytoplasm [20,98]. The first Gram-positive heme
transporter to be described was the hmu (hemin/hemoglobin utilization) system of
Corynebacterium diptheriae [99]. The hmuTUV genes share homology with Gram-negative
heme-ABC transporters such as found in Yersinia pestis [100,101]. HmuT, which is localized to
the cell membrane, binds hemin or hemoglobin directly; HmuU and V are the membrane
permease and the ATPase, respectively. Two membrane anchored heme-receptors, HtaA and
HtaB, encoded by the hmu chromosomal locus were recently described and hypothesized to work
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in conjunction with the HmuTUV transporter in heme acquisition and transport across the cell
envelope [102]. Inside the Corynebacterium cytoplasm, a heme-oxygenase enzyme, HmuO,
degrades the heme and releases the iron for use by the pathogen [73,103].
The heme uptake system studied in the most detail in Gram-positive bacteria is that from
Staphylococcus aureus and is termed the Isd (iron-regulated surface determinants) system. In the
Isd system, the IsdA, B and H (HarA) proteins are covalently attached by the SrtA sortase
enzyme to the cell wall, where they interact with a variety of ligands including heme,
hemoglobin, hemoglobin-haptoglobin complex, fibrinogen, and fibronectin [104-107]. These
proteins obtain heme and deliver it across the cell wall and the cell membrane in a cascade
fashion via IsdC and the IsdEF ABC-transporter [82,83,108]. Unlike the surface exposed Isd
receptors, IsdC is embedded deep in the cell wall by a dedicated sortase, SrtB [106,109,110].
Ligand binding by IsdA, B, C, and H (HarA) is mediated by NEAT (Near transporter) domains,
which are found in one or more copies in each of the receptor proteins.
The NEAT domain is a protein motif first identified in 2002 that is encoded in variable
copy number near ABC iron transporter genes in the chromosomes of several Gram-positive
bacterial species [39]. It is approximately 125 amino acids long with low primary sequence
homology and a predicted secondary structure of mostly β strands [39].

Expressed in

recombinant form, the isolated NEAT domains of IsdA, IsdC, IsdH (HarA) and the second
NEAT domain of IsdB (IsdBN2) have been studied and manifest different ligand preferences.
The IsdA NEAT domain has fibrinogen binding ability [104] and binds heme [111]. The IsdC
NEAT domain binds heme but not proteins such as hemoglobin, fibrinogen or fibronectin [112114]. The third NEAT domain of IsdH (IsdHN3) is also exclusively a heme-binding domain
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[115,116] and IsdBN2 binds heme as well [117]. In contrast, the two N-terminal NEAT domains
of IsdH (HarA) have demonstrated binding to hemoglobin and hemoglobin/haptoglobin,
respectively [105,118,119]. Secreted or cell wall anchored NEAT proteins which are central to
heme acquisition pathways were identified in other Gram-positive pathogens including Listeria
monocytogenes [120], Bacillus anthracis, [121,122], and Bacillus cereus [123].
Heme uptake has also been studied in Group A Streptococcus, a β-hemolytic pathogen
that uses host heme-containing proteins as an iron source [44]. One system involves a 10 gene
iron-regulated operon that has been termed Sia (Streptococcal iron acquisition) [45]. Genes three
through five in the cluster (siaABC or htsABC [53]) encode an ABC transporter that shares
significant homology with heme or siderophore transporters found in other bacterial species [45].
The second gene in the operon, shp, encodes a surface protein with β-sandwich fold similar to
that of NEAT domains and is considered a distal member of the NEAT family [49]. Shp protein
has been reported to bind heme at the cell surface and transfer it to SiaA (HtsA), the lipoprotein
component of the ABC transporter [53]. The heme coordination of SiaA has recently been
elucidated by further biophysical studies and is described as six-coordinate and low-spin,
employing methionine and histidine as axial ligands [51]. The first gene in the sia operon
encodes the Shr (streptococcal hemoprotein receptor) protein. Shr is a large (145kDa)
hydrophilic protein that does not share significant overall homology with known heme or
hemoprotein receptors [45]. The first studies of Shr revealed that it plays a role in iron
acquisition. It was observed to bind hemoglobin and hemoglobin-haptoglobin complex [45].
The transfer of heme from Shr to the protein Shp has also been described [54]. Shr was recently
demonstrated to bind the extracellular matrix proteins fibronectin and laminin, suggesting that it
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also acts as an adhesin [48]. A null shr mutant is attenuated for virulence in a zebrafish model
for necrotizing fasciitis, underscoring the importance of Shr to the infection process in vivo [48].
Shr has two NEAT domains, but its overall domain architecture, which includes a unique
N-terminal domain and a series of leucine-rich repeats, is different from any of the characterized
heme and hemoprotein-binding receptors, including the NEAT-containing Isd proteins of S.
aureus. Shr also lacks a cell wall anchoring motif typical of the Isd receptor proteins of S.
aureus; at the C terminus, Shr has a hydrophobic segment with a positively charged tail that
threads the protein through to the cytoplasmic membrane. It was recently demonstrated that Shr
spans the cell wall and is exposed to the extracellular environment [48]. Shr is proposed to
participate in the acquisition of heme by GAS and its delivery to Shp and/or the SiaABC
transporter. The uptake of heme from hemoproteins by Shr or its direct role in iron acquisition
has not been shown, however. In this study we establish the function of Shr in hemoglobin use
and heme uptake by GAS. We analyze the functional domains of this receptor protein and
present evidence that the mechanism of heme uptake by Shr is different from that of the
characterized Isd proteins. We suggest that Shr is a prototype of a new group of NEAT proteins
involved in heme uptake.
To distinguish between the two NEAT domains in Shr, the closest NEAT domain to the
amino group will be referred to as NEAT1 and the second NEAT domain from the amino group
will be referred to as NEAT2.
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Results 1

Shr is a composite NEAT protein found in pyogenic streptococci and C. novyi
NEAT domains are key ligand-binding domains used by receptor proteins involved in
heme acquisition and translocation in Gram-positive bacteria. We recently reported that the GAS
Shr protein has two NEAT domains that are separated by an LRR region [48]. Additional
sequence examination also identified an EF-hand motif between the first NEAT domain of Shr
and the LRR segment (residues 532 and 544) and two copies of a short domain with unknown
function, DUF1533 (residues 61-123 and 203-269) in the N- terminal region of Shr (Fig. 3). In
silico analysis using the web based SMART tool [124,125], reveals that there are about 160
NEAT domains in 80 proteins encoded by Gram-positive bacteria from the Firmicutes phylum.
Most of these NEAT-proteins are Isd-like molecules, which contain one or more copies of
NEAT domains, a leader peptide, and in some cases a sortase recognition signal or other type of
cell-wall binding region. A few proteins consist of an LRR segment in addition to export signals
and NEAT domain(s); these include the heme uptake protein of B. cereus, IlsA [123], and the
following hypothetical proteins A0PYT7 (C. novyi), O6HLL6 & O6HNR0 (B. thuringensis), and
073BH4 (B. cereus). Shr appears to be the first characterized protein with DUF1533 domains.
An examination of the database demonstrated that DUF1533 is found in duplication in putative
proteins with unknown function from the Clostridia class and in two species of Paenibacillus.
Therefore, the domain architecture of Shr is different and more complex than most of the
previously described NEAT receptors or the hypothetical NEAT-proteins found in bacterial
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genomes. The complex domain arrangement of Shr is intriguing and suggests that it evolved by
joining several domains found separately in bacterial proteins of Firmicutes. Shr orthologues,
which share identical or nearly identical domain architecture, are found in C. novyi as well as in
the pyogenic streptococci S. equi zooepidemicus and S. dysgalactiae (Fig. 3). A shr orthologue
is found in the genome of S. equi subsp. equi as well; however, a frame shift mutation results in a
truncated protein [126]. All streptococcal Shr orthologues are closely related in their primary
amino acid sequence (58-86% identity) while the C. novyi orthologue shares fewer identical
residues (~30%). Intriguingly, the shr gene in all the streptococci is part of a 10-gene cluster
which is homologous to the sia operon of GAS. The shr gene in C. novyi on the other hand, is
found in a genomic locus that encodes only a putative LRR-NEAT protein (A0PYT7). Together
these observations suggest that Shr may represent a new type of composite NEAT protein
family.

Shr obtains heme from solution and reduces ferric heme to ferrous heme
Shr binding to hemoproteins in vitro and its genomic location in the sia operon together
with the heme binding protein, Shp, and the SiaABC heme-transporter, suggest that Shr is
involved in heme acquisition and transport by GAS [45]. This hypothesis was recently supported
by the observation that purified Shr transfers heme to Shp [54]. The sequestering of heme from
host proteins by Shr was not previously demonstrated, however, and the mechanism of heme and
hemoprotein binding has not been investigated. To characterize heme uptake by Shr, a histidinetagged recombinant protein (rShr) [45] was prepared and analyzed (Fig. 4A). Shr is readily

17

reduced following treatment with dithionite or oxidized by ferricyanide, producing the
corresponding absorption spectra with maxima around 410 nm for the bound ferric heme or 430,
540 and 560 nm for the ferrous heme [54]. In this study we found that the spectral properties of
rShr after ferricyanide treatment were almost identical to those without treatment, with Soret
bands at 412 and 414 nm (Fig. 4B green and blue lines, respectively). On the other hand, the
addition of D, L-dithiothreitol (DTT) resulted in a shift in the absorption peak to 427 nm (Fig 4B
red line) and the production of more resolved peaks at 536 and 566 nm, spectral characteristics
of ferrous heme-protein complexes [127]. Therefore, our data indicate that rShr was purified
from E. coli as mostly ferric heme complex. In the course of Shr purification, we observed that
heme-bound rShr was considerably more stable than the heme-free protein, and that the addition
of hemin to the E. coli culture prior to harvesting the cells resulted in a higher production of
intact rShr.
Heme binding by rShr was investigated further by monitoring the changes in the UVvisible spectrum following the addition of increasing amounts of hemin (heme with ferric iron)
to the protein solution. The addition of free hemin resulted in a concomitant increase in rShrbound hemin, as was indicated by the growing absorbance at 414 nm (Fig. 4C). Surprisingly, the
UV-visible spectrum of rShr following the hemin addition also revealed growing absorption
peaks at 427 and at 540 and 564 nm as well (Fig. 4C insert). Removing the free heme by dialysis
did not lead to changes in the spectrum (data not shown). The growing peaks at 427, 540 and 564
nm indicate a simultaneous increase in rShr-bound ferrous heme. The addition of hemin to rShr
was done under aerobic conditions (using an open tube and vigorous mixing) and in the absence
of reducing agents. Therefore, the observed rise in rShr-bound heme suggests that Shr reduces
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the added hemin. The addition of ferricyanide to the protein solution following titration with 20
μM hemin resulted in a shift of the absorption peak from 427 back to 410 nm. The 410/280
absorbance ratio that is indicative of the ferric heme load in Shr [54] was changed from 0.59 to
0.75. Oxidation with ferricyanide also eliminated the peaks at 540 and 564 nm (Fig. 4D).
Therefore, ferricyanide was able to oxidize the ferrous iron of the Shr bound heme, confirming
that the changes in Shr spectrum seen following the addition of free hemin were due to a
reversible reduction of the protein-bound hemin. It was previously reported that Shr could be
purified from E. coli as a mixture of ferric and ferrous iron heme [54]. Our observations suggest
that Shr has an inherent ability to reduce the ferric heme and to provide a stable environment for
the produced ferrous complex. The autoreduction activity is a very intriguing characteristic of
Shr. To the best of our knowledge, it is the first report of heme reduction by a bacterial heme
receptor.

NEAT1 and NEAT2 are both heme-binding domains in Shr
Heme binding by the Isd proteins is imputable to their NEAT domains [128]. However
some NEAT domains have been reported to not bind heme. For example, IsdH NEAT3 domain
binds heme [115-117], whereas IsdH NEAT1 and IsdH NEAT2 domains interact only with
hemoglobin and haptoglobin [116]. Isd NEAT domains hold the heme within a hydrophobic
pocket through several conserved residues including two invariant tyrosines, one of which
coordinates the iron (Tyr 166 in IsdA) and a second residue (Tyr 170 in IsdA) that interacts with
both the heme pyrrole ring and the coordinating tyrosine [111]. Sequence analysis revealed that
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not all of the conserved residues in the Isd heme binding sites are found in Shr NEAT domains
(Fig. S1); most significantly, both of the NEAT domains in Shr are missing the iron-coordinating
residue Tyr 166, and only NEAT1 has the Tyr 170. Interestingly, the second heme binding
protein coded by the sia operon, Shp, does not use tyrosine residues to coordinate the heme iron,
and instead utilizes two methionines [49].
To investigate heme acquisition by Shr, several recombinant proteins containing one or
more of the component domains of Shr were constructed with an N-terminal fusion to the StrepTag epitope. These Shr variants include recombinant proteins with the amino terminal domain of
Shr (NTD) or the amino terminal domain through NEAT1 (NTD-N1), the NEAT1 domain, and
the NEAT2 region (Fig. 5A). The recombinant proteins were overexpressed, purified by FPLC
using a Strep-Tactin column, and analyzed. The protein containing only the NEAT1 region
turned out to be highly insoluble and was therefore excluded from further investigations. SDSPAGE analysis confirmed the production and purification of the recombinant Shr protein
fragments, revealing protein bands at the expected size for each construct: 61 kDa (NTD-N1), 42
kDa (NTD), and 23 kDa (NEAT2, Fig 5B).
The Shr protein variants that contained the first NEAT domain (NTD-N1) or the second
NEAT domain (NEAT2) both had red color when purified and a UV-visible spectrum consistent
with bound heme. The purified NTD-N1 protein showed a significant absorbance at 410 nm
indicating that it was co purified with ferric heme (Fig. 5C). In contrast, the optical spectrum of
the purified NTD fragment showed no band at the Soret region indicating that it did not contain
heme (Fig. 5D). To test the heme binding ability by Shr’s N-terminal region, the recombinant
NTD protein was incubated with increasing concentrations of hemin. The optical spectrum of the
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protein after incubation showed no absorption at the Soret region. Instead, similar to the
spectrum of free heme (Fig. S2), a broad peak at 390 nm was formed as increasing amounts of
hemin were added, indicating an accumulation of unbound heme in the NTD protein solution
(Fig. 5E). Therefore, the NEAT1 domain contained within the NTD-N1 protein is responsible for
the ferric heme binding observed by this protein fragment.
Unlike the ferric-heme load of the NTD-N1 protein, the optical spectrum of the purified
NEAT2 protein suggests that it is purified with a mixture of ferric and ferrous heme. NEAT2
spectra consistently had a significant Soret band at 428 nm along with sharp peaks at 535 nm and
564 nm. However, variations in the intensity of absorbance at 410 and 428 nm (indicating
different ratio of the protein bound ferrous and the ferric forms) were observed in the spectrum
of NEAT2 from different protein preps (Fig. 5F and the blue line in Fig. S3). To further
investigate heme binding by NEAT2, the protein was titrated with increasing concentrations of
free hemin and the UV-visible spectrum was monitored (Fig. S3). As observed with the full
length Shr, the addition of free hemin resulted in concomitant increase of absorption at around
410 nm as well as 428, 535 and 564 nm. NEAT2 was then treated with ferricyanide and the UVvisible spectrum was taken after 5 and 30 min intervals and after 24 h. Within 5 min after
addition of ferricyanide (Fig. 5G red line), the absorbance at ~410 nm increased compared to
NEAT2 without ferricyanide (Fig. 5G blue line), and the bands at ~ 428, 535, 564 nm were
almost gone, indicating that the NEAT2 protein was mostly in the oxidized form. The spectra did
not change significantly at 30 min (data not shown). After 24 h (Fig. 5G green line), a red
shoulder on the Soret band was seen, and the absorbance at 428, 535 and 564 nm had increased.
Together these observations indicated that the NEAT2 protein autoreduced slowly.

21

Methemoglobin binding is mediated by the N-terminal domain of Shr, which specifically
recognizes the holo form
Following erythrocyte lysis, the α2β2 heterodimeric hemoglobin converts to
methemoglobin, in which the heme is found in the ferric form. This is largely an αβ heterodimer
[129,130]. Methemoglobin is likely to be a physiologically relevant heme source for the
hemolytic GAS. To investigate Shr interactions with methemoglobin, we developed and used an
ELISA.

rShr and the recombinant Shr fragments NTD-N1, NEAT2, and NTD, were used to

coat the wells of microtiter plates and allowed to interact with increasing concentrations of
methemoglobin (Fig. 6A). Ligand binding by the immobilized proteins was detected using
hemoglobin antiserum. Wells coated with BSA and uncoated wells were used as controls for
non-specific interactions. rShr bound methemoglobin in a dose dependent and saturable manner,
while only low background binding (OD 405 ≤ 0.1) of the hemoglobin antiserum to the control
wells was observed. The recombinant Shr fragments NTD and NTD-N1 bound methemoglobin
with binding profiles that were similar to the full length Shr, and methemoglobin binding
appeared saturated at a concentration of 10 nM (Fig. 6A). The observation that the full length
Shr, NTD-N1 and NTD alone equivalently bind methemoglobin indicates a preponderant role for
the NTD in hemoglobin binding. In contrast, no methemoglobin binding by the NEAT2 protein
was detected. Therefore, unlike IsdA, IsdB, and IsdH proteins, which use NEAT domains to bind
hemoglobin, an uncharacterized protein pattern found in the N-terminal domain of Shr interacts
with hemoglobin.
We hypothesize that Shr interacts with methemoglobin to acquire heme from the host.
We therefore asked whether Shr could differentiate between the apo and the holo forms of
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hemoglobin. Heme was removed from methemoglobin according to Asakura et al, [131] and the
formation of the apoprotein was confirmed by the UV-visible spectrum, which revealed no
absorption at the Soret region. The binding of NTD to immobilized apohemoglobin was tested
by ELISA. In contrast to its interactions with holoprotein, no binding of NTD to apohemoglobin
was observed (Fig. 6A, red line). Similar to the NTD, the full length Shr did not bind
apohemoglobin (Fig. S4). A control ELISA performed with immobilized holo and
apohemoglobin demonstrated that the hemoglobin-specific antibody was able to detect both
forms of hemoglobin similarly over the range of hemoglobin concentrations studied (Fig. 6B).
Therefore, the absence of binding of apohemoglobin in the experimental ELISA shown in Fig.
6A (red line) was not due to a lack of ability of the hemoglobin antiserum to recognize the
apoprotein. In conclusion, these experiments demonstrate that Shr differentiates between the
holo and the apo forms of hemoglobin and binds only to heme-loaded protein.

The NEAT 2 domain in Shr mediates most of its binding to ECM
We have recently observed that in addition to its interactions with hemoproteins, Shr also
functions as an adhesin and binds fibronectin and laminin [48]. To determine the domains
involved in the ability of Shr to bind these proteins components of the extracellular matrix
(ECM), immobilized rShr, NTD, NTD-N1, and NEAT2 were allowed to react with the ECM
components using ELISAs. Ligand binding was detected with antibodies specific for fibronectin
or laminin. When fibronectin was added in increasing concentrations to the immobilized
proteins, rShr as well as the recombinant fragments NTD-N1 and NEAT2 bound it in a
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concentration-dependent and saturable manner (Fig. 7A). The NEAT2 protein demonstrated the
highest binding to fibronectin, while only low level binding was seen with NTD-N1. No
interactions with fibronectin were demonstrated by the immobilized NTD protein. These
observations suggest that NEAT regions mediate the observed Shr binding to fibronectin.
Similar observations were made with laminin; as shown on Fig. 7B, rShr, and NEAT2 proteins
bound laminin, while no significant binding to laminin was observed by the NTD or NTD-N1.
Together, these observations indicate that while both Shr NEAT domains are able to interact
with some ECM components, the NEAT2 domain plays a more significant role in this activity of
Shr.

The NTD-NEAT 1 region of Shr is sufficient for heme acquisition from methemoglobin
We next asked if the NTD-N1 fragment of Shr, which contains the hemoglobin-binding
region and the heme-binding NEAT1, is sufficient for heme acquisition from methemoglobin.
Heme was removed from the purified NTD-N1 [131], and the formation of apo NTD-N1 was
confirmed by UV-visible spectrum analysis (Fig. 8A). The heme transfer assay was done over a
Strep-Tactin column with immobilized apoNTD-N1 protein. Methemoglobin in equimolar
amounts to the immobilized apoNTD-N1 protein was flowed through the column. The bound
hemoglobin was removed by extensive washes with salt containing buffer (see Materials and
Methods), and the NTD-N1 protein was then eluted with desthiobiotin. Western blot analysis of
the fractions collected during this procedure revealed that the hemoglobin containing fractions
also included low amounts of NTD-N1 in addition to methemoglobin (lane 3, Fig. 8B),
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suggesting that some methemoglobin/NTD-N1 complexes were washed from the column. The
NTD-N1 fraction that was eluted with desthiobiotin, however, did not contain a detectable
amount of hemoglobin (lane 4, Fig. 8B). The optical absorbance of NTD-N1 after the
methemoglobin passage showed a sharp peak at 411 nm, indicating that the apoNTD-N1
acquired heme from methemoglobin (red line, Fig. 8A). To confirm that the observed absorbance
at 411 nm resulted from NTD-N1/heme complex and not from trace amounts of methemoglobin,
we analyzed the absorbance of 0.7 μM methemoglobin solution, a concentration which is above
the detection level of the hemoglobin antibody utilized in the assay (lane 6, Fig. 8B). This
analysis revealed that methemoglobin, at the tested concentration, had a significantly lower Soret
band than in the NTD-N1 fraction.
A similar experiment was done with immobilized NTD-N1 with hemin chloride solution
(in 4-fold molar excess) instead of methemoglobin in the mobile phase. The optical analysis of
NTD-NEAT1 after passage of free hemin also revealed that it acquired heme as indicated by the
peak at 412 nm (blue line Fig. 8A). However the peak at the Soret region of NTD-N1 after the
passage of methemoglobin was significantly higher than that after contact with the hemin
chloride solution. This observation suggests that the NTD-N1 protein acquires more heme from
hemoglobin than from the hemin solution, supporting heme transfer from methemoglobin
directly to the immobilized NTD-N1. Heme acquisition by apoNTD-N1 was also investigated
using an alternative assay in which the NTD-N1 was allowed to interact with methemoglobin in
solution at room temperature. The UV-visible spectrum of the NTD-N1 protein after its
separation from methemoglobin (using Strep-Tactin column) revealed a sharp peak at 410 nm
(Fig. S5), demonstrating heme transport from methemoglobin to the NTD-N1 protein.
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Interestingly, the absorption intensity at the Soret region following 5 min of co-incubation was
about 80% of that seen following 75 min, indicating rapid heme sequestering by the NTD-N1
protein.

Shr is required for GAS growth using hemoglobin as the sole iron source
To determine the importance of the heme binding domains to the function of Shr in vivo,
several GAS mutants containing in frame deletions of various regions in shr were constructed.
These include a mutant with NEAT1 deletion mutant (ΔNEAT1), a mutant with a deletion that
spans the distal part of the LRR and most of the second NEAT domain (ΔNEAT2), and a mutant
with a large deletion that includes both NEAT domains and the region in between (ΔNEAT1-2,
Fig. 9A). The production of shr alleles in the expected size in the genome of each of the mutants
and of the corresponding Shr proteins was confirmed by PCR and Western blot analyses (Fig. 9B
and 9C). This analysis also confirmed the production of the wild type Shr when the ΔNEAT1-2
was complemented. Successful complementation of the null shr mutant was previously shown
[48]. RT-PCR analysis with primers specific for siaA, which is located downstream of shr,
verified that the shr mutations were not polar and did not affect the expression of the
downstream genes in the sia operon (Fig. 9B).
The ability of wild type, a shr null mutant [48], and the isogenic mutant strains described
above to use hemoglobin as a sole source of iron was investigated using a growth assay that is
based on iron-depleted chemically defined medium (CDM). The wt strain and all of the shr
mutants grew well in complete CDM medium containing 20 μM of free iron (Fig. 9D). On the
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other hand, CDM that was prepared without iron and contained 2 mM of the ferric chelator 2, 2dipyridyl did not support significant growth of any of the tested GAS strains (Fig. 9E). The
addition of 20 μM of methemoglobin to the iron-depleted CDM restored growth of the wt strain
to the level obtained with CDM containing 20 μM iron (Fig. 9F), lower hemoglobin
concentration however, did not support growth of any of the strains in the iron depleted medium
(Fig. S6 A & B). These observations demonstrate that iron is indeed the limiting factor for GAS
growth in the 2,2-dipyridyl CDM and that GAS is able to use hemoglobin to satisfy its iron needs
as we previously reported [44]. No significant growth differences were observed between the shr
mutants containing a deletion of NEAT1 (ΔNEAT1) or of NEAT2 (ΔNEAT2) and the wt strain
in the 2, 2-dipyridyl-CDM supplemented with methemoglobin. Therefore, the ΔNEAT1 and the
ΔNEAT2 shr mutants are not affected in their ability to use hemoglobin as a source of iron. On
the other hand, the growth of the shr null mutant and to a lesser extent that of the mutant that was
missing both of the NEAT domains (ΔNEAT1-2) was impaired (Fig. 9F). The growth phenotype
demonstrated by the shr mutants was reversed by complementation with the shr gene (Fig. 9G).
These findings establish that Shr is required for hemoglobin utilization in vivo and suggest that
Shr function requires at least one of the heme binding NEAT domains. The addition of
methemoglobin in higher concentration (60 μM) supported better growth of the tested GAS
strains (Fig. S6C). Thus, the Shr-dependent pathway for hemoglobin utilization in GAS may be
of high affinity. However, additional pathways for acquisition of iron from hemoglobin also
exist, as previous findings suggest [46].
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Discussion 1
During the infection process, the β-hemolytic GAS can tap into the intracellular heme
reservoir due to the potent hemolysins it produces and satisfy its needs for iron with hemoglobin,
hemoglobin-haptoglobin, and other heme-containing proteins [44,132]. Previous observations
implicated the surface-exposed NEAT protein, Shr, in the first step of heme acquisition from
host proteins by GAS [45,54]. In this work we have provided the first direct support for this
proposition by demonstrating that Shr can obtain heme from methemoglobin and by establishing
that Shr function is important for GAS ability to use methemoglobin as an iron source. GAS use
of Shr in heme acquisition is reminiscent of NEAT-containing receptors such as the Isd proteins
in S. aureus and related proteins from other Gram-positive bacteria. In this study, however, we
demonstrate that GAS Shr structure and function are different from that of previously
characterized NEAT proteins and suggest that Shr represents a new type of protein family with a
different mode of hemoglobin binding and heme acquisition.

Shr represents a family of composite NEAT proteins
Shr is a complex NEAT protein that consists of a unique combination of domains and
protein motifs (Fig. 3). The database contains many secreted or surface proteins with NEAT
domain(s); a few also carry LRR region(s) including IlsA of B. cereus [123]. LRR are commonly
involved in protein recognition and protein-protein interactions [133]. It is possible that the LRR
may help facilitate the intra-molecular communications that are likely to take place in Shr or its
interactions with the other transport components such as Shp. DUF1533 is a domain of unknown
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function found in hypothetical proteins that contain secretion or export signals and sometimes
other functional regions including LRR. The combination of two DUF1533, a LRR region and
two NEAT domains is seen for the first time in Shr, however. Interestingly, Shr seems to be the
first characterized NEAT protein that has an EF-hand motif (located between the NEAT1 and the
LRR regions, Fig. 3). The EF-hand motif is a calcium-binding domain that is ubiquitous among
eukaryotic calcium-binding proteins such as calmodulin, but is also found in bacterial sequences
[134-136]. As with other bacterial proteins with EF-hands, the functional significance of this
motif is yet to be determined. Further in silico analysis identified several orthologues of Shr in C.
novyi, S. equi sub spp zooepidemicus, S. equi sub spp equi, and S. dysgalactiae. These Shr-like
proteins share with Shr significant sequence homology and domain architecture, suggesting that
GAS Shr is a representative of a small family of NEAT proteins that evolved by combining
domains found in surface or secreted proteins encoded by bacteria from Phylum Firmicutes.

Shr is the only NEAT protein to show ferric heme reduction
We isolated rShr with ferric heme (Fig 4B), indicating that this protein can sequester
heme from E. coli. It was previously reported that Shr could be isolated from E. coli apoprotein
with a mixture of ferric and ferrous heme [54]. When we titrated the protein with free hemin, the
increase in the absorption around 414 nm demonstrated that Shr can also acquire ferric heme
from solution (Fig. 4C). The concurrent rise in absorption at 427, 540 and 564 nm indicated
increasing amounts of rShr-bound ferrous heme and was reversed by oxidation (by ferricyanide,
Fig. 4D). This increase in bound ferrous heme following the addition of ferric heme to the
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purified rShr strongly suggests that Shr autoreduces the heme, even in air. Shr clearly provides a
stable environment for the bound ferrous heme. This is the first demonstration that Shr can
obtain heme from solution and reduce it to ferrous heme. Heme reduction is a unique property of
Shr that to our knowledge has not been reported for any other NEAT protein.
The iron oxidation state in protein-bound heme can have a significant impact on the heme
fate and its environment. For example, reduction of the ferric heme in IsdC NEAT domain
results in the loss of the heme from the protein [112]. On the other hand, the full length IsdA and
its single NEAT domain can bind both ferric and ferrous heme. The reduction to ferrous heme,
however, changes the iron axial ligand from tyrosine to histidine and renders it accessible to
small anionic ligands such as CO. Based on these observations, it is suggested that iron
oxidation/reduction lead to subsequent conformational changes with closing/opening of the
heme-binding pocket in IsdA [112,137]. Our in vitro study of rShr shows that the full-length
protein is able to bind the heme group in both the ferric and the ferrous forms as well. It seems
possible that, as in IsdA however, iron oxidation/reduction may be accompanied by structural
changes that influence the heme location within the protein (i.e., binding to first or the second
NEAT domain) or the subsequent in vivo steps in the heme trafficking such as the heme transfer
to Shp or SiaA.

30

Functional and sequence analysis show that both NEAT domains in Shr are divergent from
one another and from the NEAT domains of the Isd protein family
The optical spectrum of the Shr variants NTD-N1 and NEAT2 demonstrate that they both
complex heme, while the NTD protein, in contrast, did not show any heme binding. Sequence
alignment demonstrated that only a few of the residues that contact the heme in Isd NEAT
domains are conserved in the putative heme biding sites of NEAT1 and NEAT2 in Shr [128],
(Fig. S1). Most noticeably, both of the NEAT domains in Shr are missing the potential ironcoordinating residue, Tyr 166, a heme ligand in other NEAT proteins, and only NEAT1 has Tyr
170 (proposed to regulate heme binding and release) (Fig. S1). Therefore, the heme-binding
region in both Shr NEAT domains is quite different from that of Isd-like heme-binding NEAT
domains and the heme iron may not be coordinated by a tyrosine, at least in the NEAT2 domain
of Shr. These observations suggest that Shr NEAT domains have different mechanism for
interactions with heme. Likewise, Shp, which can acquire heme from Shr, has a unique iron
coordination involving two methionines within the single Shp molecule that function as axial
ligands [49]. Additional work is needed to determine the heme axial ligands of the NEAT
domains in Shr. Future investigations of the evolutionary relation between Shr NEAT domains
and Shp, which represents a more remote member of the NEAT family, are warranted.
Both of the NEAT domains in Shr bind heme. The optical spectra of NTD-N1 and
NEAT2 proteins as isolated from E. coli indicate that NEAT1 is complexed with ferric heme,
and that NEAT2 is bound to both ferric and ferrous heme (Fig. 5C and 5F). Like with the fulllength Shr, titration of NEAT2 with increasing concentration of hemin resulted in raising
amounts of bound ferric and ferrous heme (Fig. S3). Over time some of the ferric heme in
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NEAT2 (produced by oxidation with ferricyanide) was reduced to ferrous heme (Fig. 5G).
Together these observations suggest that the NEAT2 domain in Shr is capable of autoreduction.
Functional differences between NEAT1 and NEAT2 were also found in their interaction with
non-heme ligands. While Shr NEAT2 interacts with both fibronectin and laminin molecules,
NEAT1 binding to fibronectin is significantly weaker and it does not demonstrate significant
binding to laminin (Fig. 7).

A unique site in Shr N-terminal region mediates binding to methemoglobin
We demonstrated in this study, using ELISA with immobilized Shr variants, that the fulllength rShr, the NTD, and the NTD-N1 all bound methemoglobin similarly. The NEAT2 protein,
on the other hand, did not interact with methemoglobin (Fig. 6A). Therefore, it appears that an
unspecified region within Shr NTD mediates its binding to methemoglobin. While this
manuscript was in preparation Meehan et al [138] reported that like GAS NTD, the truncated Shr
molecule produced by S. equi sub spp equi (consisting mostly of Shr NTD) binds hemoglobin
and hemoglobin-haptoglobin complex. The finding that the interaction of Shr with
methemoglobin is not mediated by NEAT domains distinguishes Shr from the previously studied
Isd receptors. Domain analysis of IsdA and IsdH demonstrated that binding to host hemoproteins
is carried out by the single NEAT domain in IsdA and two of the NEAT domains of IsdH
[104,116]. Site directed mutagenesis localized the binding to a conserved aromatic motif also
found in the first NEAT domain of the IsdB [116], which binds hemoglobin and
hemoglobin/heptoglobin complex [107]. Consistent with the results of the ELISA experiments,
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both of the Shr NEAT domains are missing the hemoglobin binding sites identified in the Isd
proteins. Additional work is required to identify the region within Shr NTD that is involved in
hemoglobin binding. The sequence of the Shr N-terminal region is unique, and besides the two
copies of DUF1533, it shares sequence homology only with Shr orthologues. Therefore,
hemoglobin binding is mediated by a new protein motif in Shr.
Hemoglobin binding by bacterial receptors is not fully understood. In this work we show
that the Shr N-terminal domain binds only heme-containing hemoglobin (Fig. 6A). The
functional significance of this observation is that Shr may release the bound hemoglobin after
sequestering all the heme. It is not clear how Shr differentiates between the apo and the holo
forms of methemoglobin. Recognition of the heme moiety does not seem to be part of Shr
binding to methemoglobin as NTD does not bind heme and the heme is mostly buried within
hemoglobin [139]. We hypothesize, therefore, that Shr recognizes a tertiary structure in the
holoprotein that is disrupted when heme is lost, rather than recognizing a linear region within the
α or β polypeptides of hemoglobin.

The NTD and NEAT1 in Shr are sufficient for heme acquisition from methemoglobin in vitro
It was previously demonstrated that purified Shr transfers heme directly to apoShp in
vitro [54], while the direct movement of heme from methemoglobin to Shp was not observed.
Therefore it was hypothesized that Shr is involved in the first step of heme sequestering from
hemoglobin. In this study we used the column-immobilized apoNTD-N1 to ask if it could obtain
heme following transient interactions with methemoglobin or free heme (Fig. 8). Spectral
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analysis done with NTD-N1 following the passage of methemoglobin showed that it obtained
heme. In a separate assay, co-incubation of apoNTD-N1 with methemoglobin in solution
demonstrated that the heme transfer from methemoglobin is fast. NTD-N1 was also able to
receive heme from solution, but to a lesser extent. These experiments imply that heme is
transfered directly from methemoglobin to the NTD-N1 protein. Further investigations are
required to determine if NEAT2 can obtain heme from NEAT1 and/or from methemoglobin, and
to find out which of the Shr domains are required for the subsequent step in heme trafficking.

Shr is needed for heme uptake from methemoglobin in vivo
The growth of the shr- and ΔNEAT1-2 mutants in iron-depleted medium supplemented
with hemoglobin was impaired in comparison to that of the wild type GAS strain (Fig 9F). The
mutant growth phenotypes were reversed by complementation with the shr gene, establishing the
role of Shr in hemoglobin utilization in vivo. The residual growth of the ΔNEAT1-2 in low
hemoglobin concentration and the full growth of both mutants observed when higher amounts of
hemoglobin were added (Fig. S6C) are consistent with a previous report suggesting that
additional hemoglobin utilization pathways are found in GAS [46]. Since the shr mutants
required a high concentration of hemoglobin to restore growth than the wild type strain, we
suggest that Shr mediates a high affinity pathway. It is noteworthy, however, that the deletion of
a single NEAT domain (as in the ΔNEAT 1 and ΔNEAT 2 mutants) did not have significant
growth defect. These findings indicate that either one of the NEAT domains is sufficient for
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heme uptake from hemoglobin in vivo, suggesting that despite the differences found between Shr
NEAT domains, they have some functional redundancy.
In conclusion, this study establishes the role of Shr in heme acquisition from hemoglobin,
and demonstrates that the streptococcal receptor is a representative of a structurally and
functionally distinct NEAT protein family found in C. novyi and pyogenic streptococci. We have
begun to elucidate the functional domains of Shr, although additional investigations are required
to fully understand the mechanism of heme uptake mediated by this intriguing protein.

Materials and methods 1

Strains, media, and growth conditions
Escherichia coli (E. coli) DH5α and XL1 blue were used for cloning and gene expression. The
GAS strain used in this study was NZ131, an M type 49; ZE4912 an isogenic strain with a non
polar, null mutation in shr (shr::aad9) [48]; ZE4924, a merodiploid strain, which contains both
the shr::aad9 and the wild type alleles of shr in the chromosome [48]. E. coli cells were grown
aerobically in Luria Bertani (LB) medium at 37 ºC. GAS cells were grown statically at 37 ºC in
Todd-Hewitt broth with 0.2% w/v yeast extract (THY, Difco Laboratories) or Chemically
Defined Medium (CDM; SAFC Biosciences) as described in Montañez et al 2005 [46]. When
necessary, 100 µg/ml ampicillin, 100 μg/ml spectinomycin, 70 or 300 μg/ml kanamycin (for E.
coli and GAS respectively) was added to the medium.
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DNA manipulations
Chromosomal and plasmid DNA extraction and DNA manipulations, including
restriction digest, cloning, and DNA transformation into E. coli or GAS, were done according to
the manufacturer’s recommendations and with standard protocols as previously described
[140,141]. PCR for cloning was performed using the High Fidelity AccuTaq LA DNA
Polymerase (Sigma). PCR products were purified with the QIAquick PCR Purification Kit
(Qiagen). DNA ligation was done with using Fastlink ligation kit (Epicentre).

For RNA

extraction and analysis, GAS cells were harvested at the logarithmic growth phase and total
RNA was prepared using the RiboPure-Bacteria Kit (Ambion).

RNA was quantified

spectrophotometrically, and its integrity was examined by agarose gel electrophoresis. For RTPCR cDNA was produced by Superscript III reverse transcriptase (Invitrogen) according to the
manufacturer’s specification. The oligonucleotide primers used in this study are listed in Table
S1. Table S2 lists and describes the construction of the plasmids used in this work.

Strain construction
The following isogenic mutant series was constructed in NZ131 background: ZE4925 (in
frame deletion of NEAT1 in shr, ΔNEAT1), ZE4926 (in frame deletion of the LRR 3’ and most
of the NEAT2 in shr, ΔNEAT2), and ZE4929 (in frame deletion of the region between NEAT1
up to and including NEAT2 in shr, ΔNEAT1-2). Alleles with unmarked and in frame deletions
in the shr gene with about 1 Kb of flanking sequence were cloned into the temperature sensitive
shuttle vector pJRS700, as described in Table S2. The mutations were then introduced into GAS
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chromosome by transforming NZ131 cells with each of the recombinant vectors and selecting for
Kanamycin resistance at 30 °C. The transformants were then passed in antibiotic free medium at
37 °C. Mutants in shr gene, generated by allelic replacement via double homologous
recombination were identified by screening for plasmid loss (kanamycin sensitivity). The
formation of each mutation was confirmed by PCR and Western blot analysis (Fig. S5). The
GAS strains ZE4925, ZE4926, and ZE4929 were engineered using plasmids pXL2, pXL13, and
pXL3 respectively. The strain ZE4935 is a merodiploid containing both the wt and the ΔNEAT12 shr alleles in the chromosome. For ZE4935 construction, the temperature sensitive plasmid
pXL14 was introduced into ZE4929 cells and vector integration into the chromosome (via
homologous recombination) was selected on Kanamycin at 37 °C; strain construction was
confirmed by PCR and Western blot analysis (Fig. S5 and data not shown).

Overexpression and Purification of Recombinant Shr, NTD, and NTD-N1 and NEAT2
The expression of Strep-tag Shr (pEB2), Strep-tag Shr NTD (pEB10), Strep-tag NTD-N1
(pEB11), or Strep-tag NEAT2 (pHSL2) was induced with 200 ng/ml anhydrotetracycline,
overnight at 27 ºC. Cells were harvested, resuspended in lysis buffer (100 mM Tris/HCl pH 8,
500 mM sucrose, 1 mM EDTA) with the addition of 0.5 mg/ml lysozyme, β-D glucopyranoside
final concentration 0.5% and Complete, mini-EDTA-free protease inhibitor cocktail tablets
(Roche) then lysed by sonication. The cells pellet was centrifuged and the cleared lysate was
then applied to a Strep-Tactin Superflow column (IBA) with a 5 ml bed volume and purified
using FPLC. A step gradient program was used and Strep-tag proteins were eluted with 5 column
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volumes of 100 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 2.5 mM desthiobiotin. A
cation exchange column (4 ml bed volume Hi-trap SP HP, GE Healthcare) was used for further
purification of Strep-tag Shr by FPLC. The Strep-tag Shr directly after elution from the StrepTactin Superflow column was diluted 1:5 in 50 mM acetic acid pH 4.8, applied to the Hi-trap SP
HP column and eluted with 50 mM acetic acid pH 4.8 plus 1M NaCl2.
His-tagged Shr was expressed (pCB1) and purified as described previously [48] with the
following exceptions: when necessary, hemin in dimethyl sulfoxide was added to give a final
concentration of 1 µM hemin in the cell culture one hour before cell disruption by sonication and
sonication was increased to include ten cycles.
All proteins were prepared in Laemmli sample buffer and separated by sodium dodecyl
sulfate-10% polyacrylamide gel electrophoresis (SDS-10%). Western Blot analysis was
performed with polyclonal antibodies against Shr raised in rabbit as described previously [45].
Total protein concentration was measured using a Lowry assay (Pierce Biotechnology, Inc).
Each elution fraction was stored in 15% glycerol with 200 µl protease inhibitor cocktail
(Complete, mini-EDTA-free, Roche). Fractions used for further study underwent buffer
exchange to 20 mM Tris-HCl, 15% Glycerol, pH 8.0 and were stored at -20 °C.

Enzyme-linked Immunoabsorbent Assays (ELISA)
An enzyme-linked immunoabsorbent assay (ELISA) was used to analyze the ability of
Strep-tagged Shr, NTD, NTD-N1 and NEAT2 to bind to various ligands. ELISA plate wells
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(Costar, Corning, inc.) were coated with a 50 µl solution containing the desired concentrations of
bait proteins. Wells coated with BSA and uncoated wells were used as controls for non-specific
interactions. The bait proteins were diluted in PBS buffer (10 mM phosphate-buffered saline,
100 nM NaCl, pH 7.4) and included rShr, NTD, NTD-N1, NEAT2 and BSA. After the bait
proteins were incubated overnight at 4 ºC, the wells were washed with PBS-Tween (0.05%)
buffer and blocked with 200 µl 5% soy infant formula (Nestle)-PBS-Tween for 1 hour at 37 ºC
then washed again to remove blocking solution. For apohemoglobin preparation, heme was
removed from methemoglobin according to Asakura et al. [131]. The desired concentrations of
human apo/holomethemoglobin (Sigma), human fibronectin (BD) or mouse laminin (BD) in 5%
soy/PBS-Tween were then added to each well (50 µl / well). The wells were then washed PBSTween/well to remove unbound protein. Fifty µl of a 1:15,000 dilution of polyclonal rabbit antihemoglobin (sigma), rabbit anti-fibronectin (abcam) or rabbit anti-laminin (abcam) antibodies in
blocking buffer were subsequently added to each well and incubated at 37 ºC for one hour, and
the wells were then washed. Fifty µl of goat anti-rabbit IgG conjugated to alkaline phosphatase
(Sigma) at 1:6000 dilution in blocking buffer was added to each well and incubated at 37 ºC for
1h. Interactions between recombinant Shr, NTD, NTD-N1 or NEAT2 and the ligands were then
detected by adding pNPP substrate and developing the chromogenic reaction (KPN). Plates were
read at 405 nm on an automated ELISA reader for intervals up to one hour after development.
An assay to assess the ability of a variety of blocking buffers to diminish nonspecific binding
was also performed as described above except the ELISA wells were uncoated.
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rShr, NTD, NTD-N1 and N2 UV-visible spectra
The spectrophotometric analysis of samples from 250 to 700 nm was carried out using a
Varian Cary 50 Bio spectrophotometer. Absorption spectra of the purified proteins were
measured on the spectrophotometer in a quartz cell with an optical path length of 10 mm. All
absorption spectra shown in this study are representative of multiple experiments done with at
least three biological replicas.

Heme titration assays
A stock solution of hemin chloride in DMSO was prepared. The absorbance of a 1:1000
dilution of the stock solution at 404 nm was recorded and the concentration of hemin chloride in
the stock solution was calculated using Beer’s law (A= εbc where hemin in DMSO ε404=188,000
m-1cm-1 [142,143]. Protein samples were diluted in Strep-tag elution buffer to 3 μM. Absorbance
from 250-700 nm was recorded before addition of hemin chloride. Hemin chloride was added to
1 ml aliquots of 3 μM protein to a final hemin chloride concentration of 1 μM, incubated with
stirring at 4° C for 1 h and the absorbance from 250-700 nm was scanned and recorded. This was
repeated for hemin chloride concentrations of 3 µM, 5 µM, 10 µM and 20 µM. Strep-tag elution
buffer alone was similarly incubated with 1 µM, 3 µM, 5 µM, 10 µM and 20 µM of hemin
chloride. These heme-containing buffer solutions were scanned as blanks for the UV-visible
spectra of the protein solution containing corresponding concentrations of hemin chloride. The
total volume of DMSO added to the protein solutions or the blank solutions ranged from 0.15 µl
to 3 µl. Thus, the final DMSO concentration in the sample was 1.5x10-4 to 3x10-3 v/v.
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Ferricyanide and DTT treatment were done in sealed tubes with incubation at room temperature.
Ferricyanide was then removed by dialysis.

Heme transfer from methemoglobin
Heme transfer from methemoglobin to Shr fragment NTD-N1 was done using FPLC.
ApoNTD-NEAT1 was prepared according to the method described by Asakura et al [131] and
100 nmoles of the protein in 2 ml Strep-tag wash buffer were attached to a Strep-Tactin
Superflow column. Equivalent moles of methemoglobin (100 nmoles) were flowed through the
immobilized NTD-N1. The bound methemoglobin was removed by washing several times (10
column volumes) with a wash buffer (100 mM Tris-HCl pH 8.0, 250 mM NaCl, 1 mM EDTA).
Subsequently, the immobilized NTD-N1 was eluted with Strep-tag elution buffer (100 mM TrisHCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 2.5 mM desthiobiotin). Methemoglobin flow-through
and NTD-N1 elution samples were collected and analyzed by Western blot using anti-Shr and
anti-hemoglobin antibodies. Protein concentration in the different fractions was determined by
Modified Lowry assay, and Spectroscopic analysis (250 - 700 nm) of 10 μΜ apoNTD-N1 before
and after passage of methemoglobin, was carried out using a Varian Cary 50 Bio
spectrophotometer.
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Culture in microplate
All GAS strains were grown in CDM supplemented with 3 mM of L-cysteine, 15 mM of
sodium bicarbonate, 2.5 mM of magnesium sulfate, 44 μM of calcium chloride, 15 μM of zinc
chloride, 20 μM of manganese and either 20 μM of metal iron or a range of concentrations of
human hemoglobin. In the latter case, 2 mM of 2, 2-dipyridyl was added to the supplemented
CDM to completely chelate residual metal iron prior to the addition of Hb. The prepared media
were inoculated to final OD600 = 0.005. The inocula consisted of cells grown overnight at 37 °C
on blood agar and suspended in iron-free CDM. Bacterial suspensions at OD600 = 0.5 were
diluted 1:100 into the corresponding medium, which was then dispensed in 200 μl triplicates in a
96 well microplate (Costar 3595, Corning Inc.) at 37 °C for 24 h. The experiments were
performed in triplicates and were done at least twice for each strain. Kanamycin (150 μg/ml)
was added to the medium for the growth of the complemented strain ZE4924 and ZE4935.

In silico analysis
The following accession numbers were utilized for the NEAT domain-containing proteins
examined in this study: S. aureus IsdA ABX29083, S. aureus IsdC ABX29084, S. aureus IsdB
YP_001332074, S. aureus IsdH Q6G8J7, S. equi subs. zooepidemicus YP_002122760, C. novyi
NT YP_877540, S. dysgalactiae subs. equisimilis YP_002997560, S. pyogenes Shr MGAS5005
ABW80932. Identification of all protein domains was conducted by SMART analysis except the
EF-hand domain, which was identified by PROSITE. Multiple sequence alignment the NEAT
domains were executed using the ClustalW program.
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Table 1: Primers used in this study
Name

Sequence

Source

204A-FW

5’-GCTATGATGCTGTTAAGCGTGTGG

siaA

204A-Rev

5’-TCTGGAATGGCATGAGCTGTTC

siaA

Y-His-Fwd

5’-CCCCGAATTCAAATCACAAGAGCCTTTAGT

shr

Strep-shr-rev

5’-CCCCTCGAGTTATTTAAATAATGTCTTTGCACC

shr

ZE1

5’-CCCCGAATTCAAATCACAAGAGCCTTTAGTT

shr

ZE58

5’-ATCCCTCGAGGTCGACCTGCAGG

shr

ZE59

5’-CCCCTCGAGAACCTCACCTGCTTGATAAGAC

shr

ZE60

5’-TTTCTCGAGCCCAACCCCTTTTTCTTTATCATCAG

shr

ZE50

5’-AAAGGATCCACTGATGATAAAGAAAAAGGG

shr

ZE51

5’-AAAGGATCCAACCTCACCCTGCTTGATAAG

shr

ZE139

5’-CCCCGAATTCTTAAATCAAAAACAATTGCGTG

shr

ZE106

5’-TTGTAGAGGAATTCTTTTATCAGAGATATCCTC’

shr

ZE126

5’-GTAACCTTTGTGATTTGCTGAG’

shr

ZE140

5’-AAAAGGTACCTTAGACAACCTTTGCCTTCTCTG

shr

ZE168

5’- CCCCCCATCGATTCACAAGAGCCTTTAGTTCAGTCAC

shr

ZE169

5’-CCCCCCATCGATCTTATTTAAATAATGTCTTTGCACC

shr

ZE170

5’-TTTTTTATCGATTTAGCTCTTGCTGACTAG

shr

ZE171

5’-TTTTTTATCGATGGAAGCTTCAAGTTTTGCAA

shr

ZE172

5’-CCCCGGTACCTTAGGCTACCTTGGTGAATTGAGCTATTC

shr

ZE173

5’-TTTTGGTACCTGATGTTAGAGGCTCTAGCGCT

shr

ZE215

5’-TTTTTTATCGATGATCTAGATCCGACTCAAGCAAGTAAG

shr
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Table 2: Plasmids used in this study
Name

Description

Cloning method

Reference

pASKIBA-12

Step-Tag expression vector

IBA

pEB2

Strep-tag Shr

A PCR fragment was amplified from GAS
chromosome with Y-His-fwd/Strep-shr-rev
primer set, cut with EcoRI & XhoI and ligated
into pZSK-IBA-12

This study

pEB10

Strep-tag NTD

A PCR fragment was amplified from pEB2
using ZE58/ZE59 primers cut with XhoI and
self-ligated

This study

pEB11

Strep-tag NTD-N1

A PCR fragment was amplified from pEB2
using ZE58/ZE60 primers cut with XhoI and
self-ligated

This study

pHSL2

Strep-tag NEAT2

A PCR fragment was amplified from GAS
chromosome using ZE139/ZE140 primer set,
cut with KpnI and ligated into pZSK-IBA-12

This study

pCB1

Express His-tag Shr

[45]

pJRS700

Tm sensitive shuttle vector

[46]

pXL2

Carries the shr ΔNEAT1
allele

A PCR fragment was amplified from pEB8
using ZE168/ZE169 primer set, cut with ClaI
and ligated into pJRS700.

This study

pXL3

Carries the shr ΔNEAT1-2
allele

A PCR fragment was amplified from pXL2
using ZE171/ZE172 primer set, cut with KpnI
and self-ligated

This study

pXL5

Carries the shr wt gene

APCR fragment was amplified from GAS
chromosome with ZE160/ZE170 primer set, cut
with ClaI and ligated into pJRS700

This study

pXL13

Carries the shr ΔNEAT2
allele

A PCR fragment was amplified from pXL5
using ZE171/ZE172 primer set, cut with KpnI
and self-ligated

This study

pXL18

Carries shr fragment with
upstream region

A PCR fragment was amplified from GAS
chromosome with ZE215/ZE170 primer set, cut
with ClaI and ligated into pJRS700

This study

pXL14

Tm
sensitive
plasmid
expressing the wt shr gene

[48]
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CHAPTER II

MECHANISMS OF INTRA- AND INTER-MOLECULAR HEME TRANSFER BY THE
SHR PROTEIN OF GROUP A STREPTOCOCCUS

Introduction 2

Hemoglobin (Hb) and other hemoproteins that are released from lysing host cells are
major iron sources for pathogenic bacteria. Upon erythrocyte lysis, the serum carrier haptoglobin
forms a complex with Hb. Free in the blood, Hb spontaneously oxidizes to methemoglobin
(metHb) and free heme is sequestered by the plasma hemopexin. To take advantage of these
molecules, pathogens compete for the heme and transfer it across the cell envelope into the
cytoplasm, where the iron is removed or the heme is incorporated in the bacterial machinery
[98,144,145]. An emerging theme for heme transport in Gram-positive organisms is the use of a
protein relay apparatus, in which heme is obtained from host molecules and delivered in a
cascade fashion from the bacterial surface through the peptidoglycan layers to a cognate ABC
transporter. The latter then mobilizes the heme across the cytoplasmic membrane [37,38]. A
protein domain named NEAT (for NEAr-iron Transporter) often facilitates the capture and
transfer of heme by the surface receptors [37-39]. NEAT domains are found in one or more
copies in the heme-binding proteins of the different members of the Isd (Iron-regulated surface
determinant) family. These receptors are well described in Staphylococcus aureus, Bacillus
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species and Listeria monocytogenes [37-39]. Alternative heme relay apparatuses that use nonNEAT heme-binding modules were recently identified in Corynebacterium diphtheriae and
Mycobacterium tuberculosis [42,43].
Heme sequestering from host proteins in S. aureus is achieved by the cell-wall proteins
IsdB and IsdH, which transfer the heme to a third receptor in the peptidoglycan, IsdA
[107,116,117]. Heme is then passed to IsdC and then to the IsdEF proteins for import across the
cell membrane [117,146]. B. cereus relies on a surface NEAT-containing receptor (IlsA) that
interacts with uncharacterized partner proteins to import heme into the cell [123]. An Isd-like
system involving the secreted NEAT-containing hemophores, IsdX1 and IsdX2, is used by
Bacillus anthracis [40,147]. Similarly to S. aureus, heme obtained by IsdX1 and IsdX2 is
transferred to IsdC, which conveys the ligand to the cytosol through the IsdEF transporter. In
addition to IsdC, IsdX1 also transfers its heme to IsdX2.
Multiple NEAT domains may be found in a single receptor, in which case they are
numbered from the N-terminus of the protein. Isolated NEAT domains from various NEATcontaining proteins exhibit major functional differences and contribute differently to the heme
acquisition process. Many NEAT domains bind heme and/or hemoproteins [41,51,111119,148,149], whereas some also bind other ligands, such as extracellular matrix (ECM)
components [104,148]. This functional diversity is often illustrated within a single protein
harboring several NEAT domains. For example, both IsdX2 NEAT1 and NEAT5 from B.
anthracis can scavenge heme from Hb, but only IsdX2 NEAT1 can transfer its heme to IsdC
[147]. IsdX2 NEAT3 and NEAT4 can bind free heme and transfer it to IsdC, but are unable to
obtain heme from Hb. In contrast, IsdX2 NEAT2 does not bind heme, but interacts with Hb.
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In Group A Streptococcus (GAS), the conserved ten-gene operon sia (streptococcal iron
acquisition system) participates in heme uptake [45]. The first gene in the sia locus, shr,
expresses a composite surface receptor. Shr contains two NEAT domains separated by a series of
leucine-rich repeats, a unique N-terminus region (NTD) with two copies of the uncharacterized
module DUF1533 and a calcium binding EF hand [148,150]. Unlike other NEAT-containing
hemoproteins receptors, Shr (and BslK from B. anthracis) are not attached to the peptidoglycan.
Shr, which protrudes through the cell wall, is anchored to the cytoplasmic membrane by an
hydrophobic segment at its C-terminus [48], whereas BslK associates with the S-layer on the
bacterial surface [151]. Ligands recognized by Shr include heme, metHb, Hb-haptoglobin
complex and some ECM proteins [45,48]. A recent study demonstrated that Shr binds heme
through both of its NEAT domains. A separate region in Shr N-terminus mediates stable metHb
binding, but possible transient binding by other parts of the receptor are not ruled out [148].
NEAT2 interacts with fibronectin and laminin in addition to heme. The full-length Shr and a
protein fragment containing NTD and NEAT1 acquire heme from metHb in vitro [54,148].
Heme from Shr is efficiently transferred to the NEAT-like module in Shp, which is encoded by
the second gene in the sia operon. Heme is then transferred from Shp to the SiaABC (HtsABC)
transporter [152].
The sia operon is found in several pyogenic streptococci. For example, S. equi
zooepidemicus and S. dysgalactiae code for Shr orthologues with identical domain architecture.
The function of these Shr proteins in heme uptake is yet to be studied. A homologue of Shr
(SeShr) is also found in the genome of Streptococcus equi subsp. Equi; however, a frame shift
mutation in the Seshr gene results in a truncated protein that binds metHb and hemoglobin-
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haptoglobin, but not heme or fibronectin [138]. As in GAS, the Shp orthologue (SeShp) binds
heme and transfers it to the SiaABC (SeHtsABC) transporter [138,153]. In summary, heme
acquisition strategies in Streptococci share some similarity with Isd and Isd-like systems, though
important differences are found between these systems.
Here we conduct for the first time a comprehensive kinetic study to determine the role of
GAS Shr domains in heme acquisition, and we suggest a model for inter- and intra-molecular
heme flow in the streptococcal system.

Results 2
NEAT1 is more efficient in acquisition of heme from metHb than NEAT2
We recently showed that NTD-N1, a recombinant fragment of Shr containing the
domains that bind metHb and heme (NTD and NEAT1, respectively), acquires heme from
metHb in vitro [148]. To test whether NTD is essential for heme acquisition by NEAT1, we
cloned and purified a recombinant Shr fragment containing the NEAT1 domain alone fused to
maltose binding protein (MBP) (fig. S7). The molar extinction coefficient of heme-bound
NEAT1 (ε410

nm

= 136, 670 M-1 cm-1) was determined at 410 nm using the hemochromogen

method [154]. ApoNEAT1 was incubated for 5 min on ice with metHb at 2:1 apoNEAT1/metHb
molar ratio. The two proteins were then separated by affinity chromatography, allowing a
selective binding of the NEAT1 protein. Western blot analysis of the elution fraction confirmed
it contains only the NEAT1 protein without metHb contamination (fig S8). The UV-visible
absorbance spectrum of the eluted NEAT1 had the typical Soret peak at 410 nm, indicative of
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NEAT1-bound heme with ferric iron [148] (fig. 10A). These changes in the NEAT1 spectrum
suggest heme acquisition by the apoNEAT1 domain. Control heme reconstitution experiments
were carried out using 5 µM NEAT1 as purified from E. coli (fig. S9A), 5 µM MBP (fig. S9B)
or buffer only, incubated with heme in increasing concentration (fig. S9C). The initial Soret band
of NEAT1 (indicative of initial heme bound to the protein) increased significantly with the
addition of heme to the protein solution from an absorbance of 0.20 to 0.65 at 20 µM heme. In
contrast, when heme was added to MBP, the small and broad band (absorbance ~0.02) that was
visible at the Soret region slightly expanded with heme addition and reached a maximum
absorbance of only 0.071. These observations established that it is the NEAT1 domain that is
readily associating with heme in the MBP-N1 fragment, and that MBP does not contribute
significantly to these interactions. Consistent with previous observations, ELISA with
immobilized NTD, MBP-N1, MBP and BSA showed the formation of a stable complex between
metHb and NTD, and ruled out similar interactions between metHb and MBP (fig. S10).
The ability of isolated NEAT2 domain to obtain heme from metHb was tested using the
same methods. The molar extinction coefficient of heme-bound NEAT2 (ε410 nm =146, 000 M-1
cm-1) was determined at 410 nm. Western blot analysis of the eluted protein showed no metHb
contamination (fig. S8). The UV-visible absorbance spectrum of NEAT2 after metHb incubation
showed a major peak at 426 nm and peaks at 410, 530 and 560 nm, indicative of bound ferrous
and ferric heme (fig. 10B) [54,148]. Therefore, as we previously found for the acquisition of free
heme from solution by Shr [148], NEAT2 reduced some of the ferric heme it acquired from
metHb. The combined ratio Abs426nm/Abs280nm (0.51) and Abs410nm/Abs280nm (0.32) of apoNEAT2
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treated with metHb is lower than the ratio Abs410 nm/Abs280nm (2.25) of apoNEAT1 upon metHb
treatment. This suggests that apoNEAT1 acquired more heme from metHb than apoNEAT2.

The N-terminal domain of Shr facilitates heme transfer from metHb to Shr
To further investigate the transfer of heme from metHb to the different domains of Shr,
rapid reaction studies were carried out on a stopped-flow spectrophotometer. The Shr domains in
PBS were mixed individually at 25 ºC with different concentrations of metHb in PBS. Timeresolved absorbance data were collected over the entire 340-700 nm wavelength span of the
diode-array detector. Alternatively, time-courses of the reaction were collected at the wavelength
of maximal change with a monochromator and a photomultiplier detector. The time-courses of
the reactions of NTD-N1, NEAT1, NEAT2 and MBP versus metHb are shown in fig. S11. Over
time, significant changes in absorbance at 414 nm were seen only with the NTD-N1 fragment.
Therefore, in the stopped-flow experiments, NTD-N1 was the only tested fragment that
efficiently acquired heme from metHb.
Based on the observation described above, a detailed analysis of the heme transfer from
metHb to NTD-N1 was carried out. The different spectra of NTD-N1 and metHb in the apo and
holo forms are shown in fig. S12. ApoNTD-N1 at 2.5 µM final concentration was mixed with
different amounts of metHb in a stopped-flow spectrophotometer equipped with a
monochromator. The absorbance variations at 414 nm plotted as a function of time best fitted a
triple exponential process at all the concentrations of metHb tested (fig. 11A). The observed rate
constants for the fast phase (kobs1) at each concentration of metHb decreased hyperbolically with

50

increasing metHb concentration (fig. 11B). Both kobs2 and kobs3 did not show any linear or
hyperbolic dependence on metHb concentration, and had average values of 0.034 s-1 and 0.003 s1

, respectively (fig. 11C). These three kinetically distinct phases are consistent with the minimal

kinetic model that we propose in Scheme 1. In brief, NTD-N1 devoid of heme exists in solution
in two populations that are in slow equilibrium, with only one population proving able to form a
complex with metHb. Slow equilibrium is defined here as being governed by rate constants for
the interconversion of the two populations (i.e., k1 and k2 in Scheme 1) being slower than the rate
of association of metHb with apoNTD-N1. After rapid association of metHb with apoNTD-N1 to
yield a binary protein complex, the heme is transferred from metHb to apoNTD-N1, possibly
followed by the slow release of heme in solution or by the slow dissociation of the binary
complex to yield holoNTD-N1 and unloaded metHb. The presence of two populations of
apoNTD-N1 in slow equilibrium is reminiscent of a proposed kinetic model previously proposed
by Zou et al. to explain similar inverse concentration dependence kinetics for calcium (Ca2+)
binding by the Ca2+ sensor, Ca-G1 [155]. Such type of kinetics has been recently reviewed by
Vogt et al. [156]. The three well-separated phases observed in the stopped-flow
spectrophotometer provide unequivocal evidence for the presence of multiple, temporally
distinct kinetic steps. The presence of two populations in slow equilibrium and the rapid
formation of the initial protein complex are supported by the inverse concentration dependence
of kobs1, with fitting of the data to the equation: kobs1 = k1 + k2 *(Keq / (Keq + [metHb])) with R2 =
0.99, establishing the values for k1 (0.1 s-1), k2 (1.7 s-1) and Keq (32 µM). Conformational changes
or interactions with partner proteins have been shown to alter the spectral properties of proteinbound heme in several hemoprotein [157-162].
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The first phase of the minimal kinetic model proposed in Scheme 1 suggests that the
observed changes in the Soret region reflect the formation of a complex between metHb and
NTD-N1. To test whether complex formation (in the absence of heme transfer) could result in
spectral perturbations, the UV-visible absorbance spectrum of metHb (3 µM in PBS) was
compared to that of metHb in a mixture with NTD (3 and 4.5 µM respectively, in PBS). Unlike
NTD-N1, the NTD fragment can only bind to MetHb, but not heme [148]. The Soret peak of
metHb slightly decreased and shifted from 406 nm toward 408 nm in presence of NTD (fig.
S13A). The UV-visible absorbance spectrum of NTD in PBS is shown in fig. S13B. Then again,
the addition of 4.5 µM of MBP (which does not interact with metHb) to 3 µM metHb in PBS did
not lead to any change in the UV-visible absorbance spectrum of metHb (fig. S13A). It is
conceivable that like with NTD, the association of NTD-N1 with metHb leads to spectral
changes in the Soret region as proposed in Scheme 1.
The transfer of heme from metHb to NTD-N1 within the binary protein complex is
assigned to the second phase (kobs2) observed in the stopped-flow spectrophotometer, which is
defined by an average first-order rate constant of 0.034 s-1. The slowest phase (kobs3) observed in
the stopped-flow spectrophotometer had an average first-order rate constant of 0.003 s-1. The
value of kobs3 is not significantly different from the literature values for the dissociation of ferric
heme from the β subunits of human metHb (~0.002 s-1) [163]. Therefore, we suggest the third
phase corresponds to the dissociation of heme from metHb in solution that occurs after the heme
transfer within the binary protein complex. Alternatively, the third phase may represent the slow
dissociation of the holoNTD-N1-apometHb complex.
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One possibility for the two populations inferred in resting NTD-N1 by the kinetic
analysis is because of different oligomerization states of the protein. Analytical gel filtration was
performed to evaluate the oligomerization state of NTD-N1 in solution. The molecular weight
(MW) of NTD-N1 was determined by comparing its elution volume with those of known protein
standards (aldolase, catalase and bovine serum albumin) on a Superose-6 10/300 column (GE
Healthcare) in PBS. Most of the NTD-N1 protein in these experiments was excluded from the
column with an elution volume (15.7 ml, fig. S14A) that was similar to that of aldolase (MW of
160 kDa, elution volume 15.4 ml, fig. S14B), thereby establishing a MW of ~140 kDa for NTDN1, consistent with the presence of NTD-N1 dimers (~142 kDa).

Heme transfer from metHb to the full-length Shr
The kinetics of heme acquisition from metHb by the full-length Shr was carried out and
compared to the heme transfer between metHb and the NTD-N1 fragment. Stopped-flow
experiments were conducted by mixing various concentrations of metHb in PBS with 2.5 µM
apoShr in PBS. The changes in the absorbance at 414 nm recorded over time indicated a triple
exponential process (fig. 12A). The observed rate constants of the first and second phases (kobs1
and kobs2) increased hyperbolically with increasing metHb concentration (fig. 12B & 12C). The
limiting rate constants were determined as the asymptotic estimates at high metHb
concentrations, with values of 6.5 ± 0.7 s-1 (R2 = 0.99) for the fast phase, which defines an
intercept of 1 s-1 on the y axis, and 2.3 ± 0.6 s-1 (R2 = 0.99) for the second phase. The observed
rate constants of the third phase (kobs3) did not show an unequivocal dependence on metHb
concentration with kobs values that could be fit either with a hyperbolic saturation dependence or
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a linear dependence (fig. S15). Each fit returned a rate constant value for kobs3 at infinite
concentration of metHb of ~0.15 ± 0.07 s-1.

NEAT1 mediates rapid heme transfer to Shp
Heme transfer from Shr to Shp has been previously reported [54]. However, the role of
Shr NEAT domains in the process was not studied. To determine whether the two NEAT
domains of Shr constitute heme sources for Shp, stopped-flow experiments were carried out. Shp
was cloned and the recombinant protein was purified by affinity chromatography (fig. S7). The
molar extinction coefficient at 410 nm (ε410

nm

=116, 000 M-1 cm-1) and the UV-visible

absorbance spectrum of the heme-bound recombinant Shp were determined (fig. S16). ApoShp
at a final concentration of 2.5 μM was mixed in a stopped-flow spectrophotometer with various
concentrations of holo NEAT1 or NEAT2, and the spectral changes were monitored over the
entire 340-700 nm wavelength range of the diode-array detector. The time course of the reactions
for holoNEAT1 versus apoShp best fitted a double exponential process (fig. 13A), with both
observed first-order rate constants being linearly dependent on the concentrations of
holoNEAT1. The second-order rate constants estimated from the slopes of the plots in fig. 13B
and 13C were 2.50 ± 0.04 s-1 μM-1 (R2 = 0.99) for the fast phase (fig. 13B) and 0.017 ± 0.004 s-1
μM-1 (R2 = 0.89) for the slow phase (fig. 13C).
The time course of the reactions for holoNEAT2 versus apoShp also best fitted a double
exponential process (fig. 13D). The observed rate constants for the fast phase showed a
saturation behavior dependent on the concentration of holoNEAT2, with a rate limiting value at
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saturating NEAT2 of 0.010 ± 0.001 s-1 (fig. 13E). The apparent first-order rate constants for the
slow phase were nearly independent of the concentrations of holoNEAT2, with an average
observed rate constant of (2.1 ± 0.5) x 10-5 s-1.

Heme exchange between Shr NEAT domains
We sought to determine whether NEAT2 could acquire heme from NEAT1. ApoNEAT2
was mixed with holoNEAT1 at 2:1 apoNEAT2/NEAT1 molar ratio for 5 min. NEAT2 was then
separated from NEAT1 by affinity chromatography, allowing a selective binding of the NEAT2
fragment. Eluted NEAT2 was analyzed by SDS-PAGE and showed no NEAT1 contamination
(fig. S17). The UV-visible spectrum of NEAT2 after incubation with NEAT1 revealed two major
peaks at 410 nm and 426 nm, corresponding to bound ferric and ferrous heme, respectively (fig.
14A). Time course of the heme transfer from NEAT1 to NEAT2 was monitored in a stoppedflow spectrophotometer equipped with a monochromator, mixing apoNEAT2 (2.5 μM final
concentration) with different concentrations of holoNEAT1. The time course of the heme
transfer was biphasic and best fitted a double exponential process. The fast phase was linearly
dependent on the concentration of holoNEAT1. A second-order rate constant of 0.15 ± 0.02 s-1
μM-1 (R2 = 0.94) was obtained from the slope of kobs1 vs holoNEAT1 concentrations (fig. 14B).
The slow phase exhibited no significant dependence on NEAT1 concentration and had an
average observed rate constant of 0.06 ± 0.01 s-1. In a similar experiment using holoNTD-N1 as
heme donor to apoNEAT2, the reaction best fitted a single exponential. The observed rate
constants were linearly dependent on holoNTD-N1 concentration. The second order rate constant
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for heme acquisition was determined as above and resulted in a value of 0.66 ± 0.05 s-1 μM-1 (R2
= 0.99). Therefore, Shr NTD contributes only slightly to the transfer of heme from NEAT1 to
NEAT2. To test whether NEAT2 can readily transfer its heme back to NEAT1, time course of
the reaction of heme transfer from holoNEAT2 (35 μM) to apoNEAT1 (2.5 μM) was carried out.
The spectral changes were monitored at 427 nm. The reaction best fitted a double exponential
process, with an observed rate constant at saturating concentration of 1.1 ± 0.2 s-1 for the fast
phase. The observed rate constant of the second phase was negligible (0.003 ± 0.003 s-1).

Discussion 2
Heme flow between proteins and/or isolated NEAT domains was studied in various Isdproteins from S. aureus and B. anthracis. Despite the overall similarity in the organization of the
heme relay systems and protein homologies, the transfer process appears to be different in
different proteins. In several cases, heme shuttle is mediated by an active process involving
protein-protein interactions, as is found in the transfer from IsdA to IsdC [146] and from IsdB to
IsdA [149] in Staphylococcus and the transfer between bacilli proteins IsdX1 to IsdC [40]. In
other examples, including the acquisition of heme by IsdH from Hb in S. aureus [116] and the
transfer of heme from IsdX2 to IsdC of B. anthracis [147], heme transport is suggested to be
passive, mediated by heme dissociation and capture from solution. The Sia heme relay system in
GAS is different from those characterized in Bacillus and Staphylococcus by the number and the
nature of the interacting proteins. In addition, the mechanism of heme transport was investigated
in detail only for the relay between Shp and SiaA, the binding protein of the SiaABC
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transporters. Here we carried out analyses of the functional domains in Shr, the first receptor in
the relay, and assessed the domains’ role in heme acquisition and delivery to Shp.
We previously established that both NEAT1 and NEAT2 could capture free heme from
solution [148]. In this study, we found that the measured values of the Soret/280 nm ratio after
incubation of apoNEAT2 and apoNEAT1 with metHb and separation by affinity
chromatography were ~0.83 and ~2.25, respectively. This absorbance ratio is commonly used as
an estimation of heme content [147,164,165] and suggests that the process of heme uptake from
metHb is more effective with NEAT1 than it is with NEAT2 (fig. 10A & fig.10B). However, in
the stopped-flow experiments conducted with isolated Shr fragments, only the NTD-N1 fragment
could efficiently acquire heme from metHb, while NEAT1 and NEAT2 did not (similar
observations were made with independent protein preparations). There is no obvious basis for the
difference in the capacity to obtain heme from metHb observed with isolated NEAT domains in
the static heme transfer, versus the rapid reaction experiments. It seems possible, however, that
the higher concentration of NEAT-proteins needed for the heme transfer experiments carried out
on a column, in comparison to that needed for the stopped-flow (40 μM and 2.5 μM,
respectively), may favor a protein state, much like a certain fold or oligomerization status that is
prone for heme uptake. Enzyme concentration was shown to affect reaction kinetics in some
cases [166]. The inclusion of the metHb-binding region, NTD, in the NTD-N1 fragment may
have increased heme capture by NEAT1 by possibly fostering stable interactions with metHb, or
shifting the protein population balance towards the state that favors heme uptake. The suggestion
of two protein populations, only one of which participates in heme uptake, is also consistent with
the kinetics of heme uptake by NTD-N1 as discussed below.
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Heme transfer from metHb to IsdH NEAT3 is ~2-fold faster in the presence of the
metHb-binding domain, IsdH NEAT1 [116]. Nevertheless, substantial differences exist between
the heme transfer events mediated by Shr NTD-N1 and IsdH. On the one hand, heme transfer
from metHb to IsdH NEAT3 in presence of IsdH NEAT1 is a slow biphasic process with rate
constants similar to the rate constant of free dissociation of heme from metHb [116]. Conversely,
Shr NTD-N1 fragment obtained heme from metHb faster and in a unique three-phase process
that was not seen in other characterized heme relays: a rapid first phase with apparent rate
constants that decreased hyperbolically with the increase in metHb concentrations (fig. 11B),
followed by the second and third phases that did not show linear or hyperbolic dependence on
metHb concentrations. While the average rate constant of the third phase does not deviate
significantly from that of free dissociation of heme from the β-subunit of metHb (~0.002 s-1)
[163], the rate constant of the second phase is ~20-fold higher. The inverse correlation between
the apparent rate constants and metHb concentrations observed during the first phase is
consistent with the minimal kinetic model proposed in Scheme 1, and is explained by a slow
interconversion between two forms of apoNTD-N1 that are present in solution, with only one
form that binds metHb in a productive fashion that results in the subsequent heme transfer. The
increasing amount of metHb added to the mixture progressively altered the equilibrium, due to
the formation of a complex between metHb and the binding form of apoNTD-N1. Formation of
different multimeric states is one of the possible explanations for the coexistence of different
forms of apoNTD-N1. Dimers formation by NTD-N1 was supported by the analytical gel
filtration experiments, and ELISA confirmed that stable interactions between NTD and metHb
are formed (fig. S10, S14 and [148]). The first step of Scheme 1 implies that complex formation
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without heme transfer results in the spectral changes. This hypothesis was supported by the
changes observed in the UV-visible absorbance spectrum of metHb when it was incubated with
NTD, but not with MBP. During the second phase, the intermediate complex apoNTD-N1metHb may facilitate the transfer of heme from the metHb directly to NEAT1 (Scheme 1). The
third phase may represent the release of heme in solution from the β-subunit of metHb, as
suggested by the low observed rate constants. Alternatively, it may represent the slow
dissociation of the holoNTD-N1-apometHb complex.
Like the isolated NTD-N1, the full-length protein acquired heme from metHb in a time
course that best fitted a triple exponential equation at all tested metHb concentrations. However,
the observed rate constants for the first and second phases were hyperbolically dependent on
metHb concentration, whereas the observed rate constants of the third phase did not show an
unequivocal dependence on metHb concentration (fig. 12B & C and fig. S15). The fit of kobs1
values defines a y intercept of 1 s-1, which corresponds to the reverse of the heme transfer to
NEAT1 domain. The first and second phases were ~190 and ~65 times faster, respectively, than
the second phase of heme transfer from metHb to apoNTD-N1. We propose that these two
phases correspond to the direct heme transfer from metHb to NEAT1 and to NEAT2,
respectively (Scheme 2), with the first process ~3 times faster than the second (6.5 ± 0.7 s-1
versus 2.3 ± 0.6 s-1). The third phase may correspond to the dissociation of the Shr-metHb
complex (Scheme 2). Protein-protein interactions involving hemoproteins and cognate partners
can result in changes of the absorbance properties of the bound heme ([157-162] and fig S13A).
In summary, although both the NTD-N1 fragment and the full-length Shr acquired heme from
metHb in a three-phase process, significant differences are found between the mechanisms
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involved. The full-length protein, which contains two heme-binding domains, scavenged heme
from metHb several fold faster than NTD-N1.
Shp, the adjacent protein to Shr in the Sia system, does not efficiently acquire heme from
metHb, but readily scavenges it from Shr [54]. The stopped-flow kinetics experiments in this
study revealed that holoNEAT1 transfers heme to apoShp in a two-phase process with second
order rate constants of 2.5 ± 0.04 s-1 μM-1 and 0.017 ± 0.004 s-1 μM-1, and with both phases
linearly dependent on holoNEAT1 concentrations (fig. 13B and C). This observation is
indicative of two heme transfer events occurring simultaneously from two species of
holoNEAT1 to apoShp, with one species transferring its heme ~150 times faster than the other
species (Scheme 3). Different multimeric states, other protein rearrangements or the presence of
a certain fraction of protein not fully competent for heme uptake, may be invoked to explain the
presence of two phases here. Similarly, two phases were observed in the transfer reactions
between holoNEAT2 and apoShp. The fast phase was dependent on the concentration of
holoNEAT2 in a saturable manner, and the slow phase was independent of holoNEAT2
concentrations. The observed limiting value at holoNEAT2 saturation of the fast phase (0.01 ±
0.001 s-1) is comparable to the observed rate constant of the slow phase in the transfer reactions
between holoNEAT1 and apoShp. In conclusion, NEAT1 appears to donate heme directly to Shp
probably by an active process, whereas heme transfer from NEAT2 to Shp is a slow process that
likely relies on the free dissociation of heme in solution. Finally, since the rate constant of the
slow phase observed in the transfer reaction between holoNEAT2 and apoShp was nearly equal
to zero, it may be an artifact due to damaged or not fully functional protein.
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Here we explored the heme flow within Shr using both qualitative and quantitative
assays. ApoNEAT2 efficiently acquired heme when mixed in excess with holoNEAT1. The
kinetics of heme transfer from holoNEAT1 to apoNEAT2 showed that this reaction was ~17
times slower than the reaction of heme transfer from holoNEAT1 to apoShp, indicating that
NEAT1 preferentially transfers its heme to Shp rather than to NEAT2. The reverse heme transfer
reaction from holoNEAT2 to apoNEAT1 suggested that NEAT2 transfers heme to NEAT1 faster
than it receives heme from NEAT1. This implies that the transfer of heme from NEAT1 to
NEAT2 only occurs as an alternative, probably in situations where heme is present in excess.
The observed differences in the ability of Shr NEAT domains to obtain and transfer heme
illustrate an example of functional diversity of these protein modules when present in multiple
copies within a single protein. Another example of NEAT functional diversity is evidenced by
the five NEATs of IsdX2 hemophore in B. anthracis [147].
Taken together, our results shed light on the intra- and inter-molecular mechanisms of
heme acquisition and transfer by Shr. We propose that Shr binds metHb through NTD and forms
an intermediate protein complex, which may facilitate direct heme transfer from metHb to
NEAT1 and NEAT2, and eventually the release of heme from metHb in solution. Heme
scavenged by NEAT1 is rapidly transferred to Shp for delivery into the cell by the SiaABC
transporter. Heme acquired by NEAT2 is stored and transferred back to NEAT1 when needed,
possibly when heme availability is limiting (fig. 15). The hemolytic GAS can colonize a variety
of sites in the human body, including the mucosal membranes in the upper respiratory tract and
the skin. This pathogen could also spread via blood and various tissues producing bacteremia,
massive necrosis, or both. Therefore, during infection, GAS is confronted with a changing
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environment where iron and heme could be highly restricted or toxic in excess. The possible
function of Shr as a modulator of heme uptake, as raised by this investigation, could be very
important for GAS adaptation during the infection process.
While this manuscript was in preparation, a study [167] was published suggesting that
apoShr obtains heme from metHb in a biphasic process with reaction rate constants of 0.027 s-1
and 0.0042 s-1. Those measurements were carried out at a single metHb concentration without
evaluation of their dependence on metHb concentration [167]. In the present study, we tested
heme transfer from metHb to apoNTD-N1 and to apoShr across multiple concentrations of
metHb. This comprehensive analysis allows us to establish that heme uptake from metHb
involves a three-phase process with reaction rate constanzts of 6.5 s-1, 2.3 s-1 and 0.15 s-1 under
saturating conditions. For the transfer to Shp, we found in this study that while isolated NEAT1
readily gives its heme to Shp, NEAT2 does not. This inefficient transfer of heme from NEAT2 to
Shp might explain the partial heme transfer with the full-length Shr (37% of the heme is not
transferred) recently reported by Lu et al [167].

62

Materials and methods 2
The bacterial strains, media and antibiotics
Escherichia coli (E. coli) cells were grown aerobically in Luria–Bertani (LB) medium at 37 °C
supplemented with 100 µg/ml of ampicillin. The E. coli strains used in this study are listed in
Table 3.

Recombinant Shr and Shp proteins
The plasmids and primers used in this study are listed in Tables 3 and 4. The cloning of the
recombinant Shr proteins, NTD-N1 (pEB11) and NEAT2 (pHSL2), each expressed as Nterminal fusion to the Strep-Xpress® epitope was previously described [148]. Shr NEAT1
fragment is insoluble when expressed as an isolated domain [148]. MBP was previously shown
to help in the solubility of recombinant proteins; therefore, an N-terminal fusion of Shr NEAT1
to His-MBP was constructed. Cloning was performed using the Gateway® technology
(Invitrogen) according to the manufacture protocol. In brief, NEAT1 region was amplified from
NZ131 chromosome with ZE353/354 primer set and was cloned into the entry vector
pDONRTM221 by BP ClonaseTM II. The resulting entry clone, pYSH5, which carries NEAT1
fragment flanked by the attL sites, was then allowed to interact with the destination vector
pDEST-His tag-MBP. The produced plasmid, pYSH6, expresses a His-tag-MBP-NEAT1 fusion
protein from the TAC promoter. The construction of Shp-His expression vector was
accomplished by TOPO® directional cloning according to the manufacturer instruction
(Invitrogen, K101-01). The shp ORF was amplified from NZ131 chromosome using the
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ZE406/ZE407 primer set and introduced into the pET101/D-TOPO vector. The resulting plasmid
pOM101 codes for a Shp-His tag fusion protein expressed from the T7 RNA polymerase
promoter.

Proteins expression and purification
NTD-N1 and NEAT2 were prepared as previously described [148]. Expression of His-tagged
MBP-NEAT1 and His-tagged Shp was induced overnight at 27 °C with 1mM isopropyl β-D-1thiogalactopyranoside. Cells were harvested and resuspended in an extraction buffer (20 mM
Tris pH 8, 100 mM NaCl, 0.1% Triton X-100) with the addition of 0.5 mg/ml and Complete,
mini-EDTA-free protease inhibitor cocktail tablets (Roche), then lysed by sonication. The cells’
pellet was centrifuged and the cleared lysate was then applied to a 5 ml HisTrap HP affinity
column (nickel column) and purified using a FPLC. Purified proteins were dialyzed in PBS
buffer (10 mM phosphate-buffered saline, 100 mM NaCl, pH 7.4) prior to their use for
experiments. Western blot analysis of recombinant Shp was carried out using anti-His antibodies
from mouse (Sigma).

Preparation of apoproteins, measurement of heme and protein concentrations
Preparation of apoproteins and total protein measurements were performed as previously
described [148]. Heme concentration was determined by the absorbance at 410 nm using Beer’s
law (A= εbc, where ε is the molar extinction coefficient at 410 nm of the corresponding heme-
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bound protein, b is the path length of the sample and c is the concentration of heme in the
sample).

Heme transfer experiments
ApoNEAT1 and apoNEAT2 (200 nmoles of each protein in 2 ml of PBS) were mixed with
metHb (100 nmoles in 3 ml of PBS). The final concentrations of apoNEAT proteins and metHb
in the 5 ml mixtures were 40 and 20 µM, respectively. After 5 min, the mixtures were then
loaded on a HisTrap HP affinity column or Strep-Tactin Superflow column, respectively, to
separate the Shr fragments from metHb. Trace metHb was removed by washing several times
(10 column volumes) with His-tag wash buffer (20 mM sodium phosphate pH 7.4, 500 mM
NaCl, 30 mM imidazole) or Strep-tag wash buffer (100 mM Tris-HCl pH 8.0, 250 mM NaCl, 1
mM EDTA). Subsequently, the immobilized proteins were eluted with His-tag elution buffer (20
mM sodium phosphate pH 7.4, 500 mM NaCl, 500 mM imidazole) or Strep-tag elution buffer
(100 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 2.5 mM desthiobiotin). Spectroscopic
analysis (250-700 nm) of the apoproteins before and after treatment with metHb was carried out
using a Varian Cary 50 Bio spectrophotometer. All UV-visible spectra were subtracted from
their corresponding background absorbance at 700 nm. The same procedure was used for heme
transfer from NEAT1 to NEAT2, with the exception that apoNEAT2 (200 nmoles in 2 ml of
PBS) was mixed with holoNEAT1 (100 nmoles) for 5 min and the two proteins were separated
using a Strep-Tactin Superflow column.

Heme reconstitution, Enzyme-Linked ImmunoSorbent Assays (ELISA)
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The heme reconstitution and ELISA experiments were conducted as described in [148].

Stopped-flow analysis
Rapid kinetics was carried out on a Hi-Tech SF-16 stopped-flow spectrophotometer. The
reacting apoproteins were mixed individually in PBS at 25 ºC with different concentrations of
the corresponding holoprotein. All concentrations of heme-loaded proteins were based on the
absorbance of heme bound to the protein. All concentrations used maintained pseudo-first order
conditions. Absorbance data were collected over the entire 340-700 nm wavelength span of the
diode-array detector. Alternatively, time-courses of the reaction were collected at the wavelength
of maximal change with a monochromator. The optical path length for all the stopped-flow
experiments was set to 2 mm.

Data analysis
The absorbance traces at individual wavelength were analyzed using KinetAsyst 3 software (HiTech Scientific) and KaleidaGraph (Synergy Software). Transients were fitted using the standard
double or triple exponential expression (eq. 1, 2)
A = C1e-kobs1t + C2e-kobs2t +b

Eq. 1

A = C1e-kobs1t + C2e-kobs2t +C3e-kobs3t+b

Eq. 2

Where A is the absorbance at selected wavelength, kobs1, kobs2 and kobs3 are the observed rate
constants for the different phases, respectively; C1, C2 and C3 are the relative amplitude values
for the different phases; and b is an offset value to account for a non-zero baseline.
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Table 3: Strains and Plasmids used in this study
Name

Description

Source/Reference

E.coli Top10

Host for pOM101 propagation

Invitrogen

E.coli BL21 Star

Host for pOM101 expression

Invitrogen

E.coli One shot Omni Max2-TI

Host for pYSH6 expression

Invitrogen

pEB11

Expresses Strep tag-NTD-N1 from Ptet

[148]

pHSL2

Expresses Strep tag-NEAT2 from Ptet-

[148]

pDONRTM221

Gateway® Donor vector with attP sites

Invitrogen

pDEST-His tag-MBP

Gateway® Destination vector with attR sites

[168]

pYSH5

attL-NEAT1-attL entry vector

This study

pYSH6

Expresses His tag-MBP-NEAT1 from Ptac

This study

pET101/D-TOPO

Directional TOPO® TA cloning vector

Invitrogen

pOM101

Expresses Shp-His tag from PT7

This study

Strains

Plasmids
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Table 4: Primers used in this study

Name

Sequence

ZE353

GAGAACCTGTACTTCCAGTCTTATCAAGCAG

Sense primer for Shr NEAT1

GTGAGGTTTCT

domain

GGGGACCACTTTGTACAAGAAAGCTGGGTA

Anti-sense primer for Shr

TTAATCATCAGTTTCTACCTGATAACC

NEAT1 domain

ZE406

GATAAAGGTCAAATTTATGGATG

Sense primer for shp

ZE407

GTCTTTTTTAGACCGAAACTTATC

Anti-sense primer for shp

ZE139

CCCCGAATTCTTAAATCAAAAACAATTGCGT

Sense primer for Shr NEAT2

G

domain

AAAAGGTACCTTAGACAACCTTTGCCTTCTC

Anti-sense

TG

NEAT2 domain

ZE354

ZE140

Description

primer

for

Shr
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CHAPTER III

DISCOVERY OF HUPZ, THE FIRST STREPTOCOCCAL HEME OXYGENASE

Introduction 3
The restriction of free iron in the mammalian host constitutes a severe limitation to
bacterial infections. Most of the biologically available iron in mammalians is bound to
protoporphyrin IX in heme molecules, the vast majority of which are sequestered by proteins.
Bacterial pathogens overcome this nutritional sequestration using elaborated systems that allow
them to scavenge and transport heme from host hemoproteins into the bacterial cell
[37,98,144,145]. A few mechanisms then allow bacteria to retrieve iron from the porphyrin
center [56]. The most common one relies on oxidative degradation of the porphyrin ring by
cytoplasmic enzymes known as heme oxygenases (HO) [57]. When supplied with electron
donors, the canonical HOs break down heme to CO, α-biliverdin and free iron [60,169].
The first bacterial HO discovered is HmuO, a homologue of the human HO-1 found in
the pathogen Corynebacterium diphteriae [72,73]. Subsequently, several other HOs were
identified and characterized in Neisseria meningitides (HemO) [74], Clostridium species
(HemO) [75,76] and Pseudomonas aeruginosa (PigA or pa-HO and BphO) [77,78]. Like the
mammalian HO-1, all of these HOs consist of monomeric α-helices with similar folds and
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degrade heme to α-biliverdin [66], with the exception of PigA which produces an unusual
mixture of β- and δ-biliverdin [77].
A group of bacterial HOs that are structurally different from the mammalian HO-1 is
represented by IsdG and IsdI from Staphylococcus aureus. The structure of enzymes from the
IsdG family consists of a homodimeric β-barrel with two separate active sites [82,83]. Unlike
HmuO-type enzymes, IsdG catalyze the production of staphylobilin, an oxo-bilirubin
chromophore and not biliverdin [81]. Members of the IsdG family include HmuD and HmuQ
from Bradyrhizobium japonicum [84], MhuD from Mycobacterium tuberculosis [85] and the
IsdG homologues from Bacillus anthracis [87] and Staphylococcus lugdunensis [86].
A separate group of heme degrading enzymes whose products are not characterized was
described in some pathogens including HemS from Yersinia enterocolitica [89], ChuS from
Escherichia coli [88] and HemS homologue from Bartonella henselae [90]. Biochemical data
supporting heme degradation in the presence of reducing agents was only shown for the last two
examples [88,90]. The high sequence homology shared by these three proteins suggests their
relatedness. The crystal structure of ChuS revealed a unique structure consisting of two central
sets of antiparallel β-sheets, each flanked by two pairs of α-helices [88].
A new family of bacterial HOs with no homology to previously described enzymes was
recently uncovered in Campylobacter jejuni (Cj1613c) [91], Helicobacter pylori (HugZ) [92]
and Vibrio Cholerae (HutZ) [93]. Members of this family share weak sequence similarities with
FMN-binding proteins and form dimers [93,94]. The crystal structure of HugZ was recently
resolved; this protein adopts a split β-barrel fold that is characteristics of FMN-binding proteins,
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however, actual FMN binding was not demonstrated. [94]. This structure is distinctive from that
of HmuO-like or IsdG-like proteins. Interestingly, like PigA, HugZ has a unique δ-meso
regiospecificity for cleaving the ring in the heme molecule [92], whereas HutZ is proposed to
have both β- and δ-meso regioselectivity [93].
Heme uptake in Group A Streptococcus (GAS) is mediated by a conserved ten-gene
operon, sia (streptococcal iron acquisition system) that is directly repressed by the irondependent regulator MtsR [45,47]. Shr, the product of the first gene in the sia locus is a complex
surface receptor. It contains two heme-binding NEAT domains separated by a series of leucinrich repeats, a calcium binding EF hand and a unique N-terminus region (NTD) which harbors
two uncharacterized DUF1533 modules [148,150]. Shr is attached to the cytoplasmic membrane
by a hydrophobic tail located at its C-terminus and is exposed at the bacterial surface by
protruding through the peptidoglycan layer [48]. Different regions of the protein recognize and
interact with various ligands including heme, methemoglobin (metHb), hemoglobin-haptoglobin
complex and some ECM proteins [45,48,148]. The full-length Shr and a fragment of the protein
that includes NTD and NEAT1 (NTD-N1) obtain heme from metHb in vitro [54,148]. Heme
acquired by Shr is efficiently transferred to Shp, the protein encoded by the second gene in the
sia operon, which in turn transfers it to the SiaABC (HtsABC) transporter [152]. Recent kinetic
and spectroscopic analyses indicate that Shr and NTD-N1 fragment scavenge directly heme from
metHb by two distinct and unprecedented three-phase processes. Additionally, NEAT1
efficiently transfers its heme to Shp in a biphasic process, whereas NEAT2 does not and may
serve as temporary heme storage on the bacterial surface. Furthermore, a reversible heme
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exchange occurs between NEAT1 and NEAT2, constituting the first example of intra-molecular
heme transfer between NEAT domains.
The fate of the imported heme inside the streptococcal cell remains unknown, as to date,
a heme oxygenase has not been identified in Streptococci. Herein, we report the identification of
the first heme oxygenase described in the Streptococcus genus. We provide biochemical
evidences for heme binding and degradation by the enzyme and we show that it is the
representative of a new family of heme oxygenases.

Results 3
Heme binding by HupZ
GAS utilizes host heme containing proteins as iron source during infection [44]. This
implies that the bacterium possesses mechanisms that allow it to retrieve iron from heme. This
function is commonly carried out by HOs which catalyze the enzymatic cleavage of the
porphyrin ring releasing free iron, CO and biliverdin [60]. Homologues of HOs are absent from
the streptococcal genome, raising an intriguing mystery regarding heme utilization by GAS.
Microarray analysis of MtsR-regulated genes identified putative gene (Spy49_0662) that was
overexpressed in the mtsR mutant strain, suggesting its implication in iron or heme metabolism
[170]. Spy49_0662 translates into a small protein of about 18.5 kDa with no secretion signal
indicating that the protein likely functions in the cytoplasm. In silico analysis showed that this
protein contains a module that belongs to the superfamily of the signature domain of the
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pyridoxamine 5'-phosphate oxidase (PNPOx). The PNPOx domain is found in FMN binding
enzymes.
To test its role in iron utilization, we cloned and expressed Spy49_0662 from M49 GAS
in E. coli as a C-terminal fusion to hexa-histidine tag. The recombinant protein was purified on
an affinity column using FPLC. The cell lysate had a yellow color that was retained in the
affinity column during purification. However, the yellow substance was separated from the
protein and was eluted out of the column in different protein-free fraction. SDS-PAGE analysis
confirmed the presence of a single protein band that migrated to the expected size of 18.5 kDa
(fig. S18A). Subsequently, UV-visible spectroscopic analysis was conducted on the different
fractions and revealed that the absorbance spectrum of the yellow fraction is consistent with that
of oxidized FMN (fig. S18B). In contrast, the spectrum of the purified recombinant protein
included bands at 334 and 405 nm (fig. S18C) which suggest that it is co-purified with reduced
FMN [171]. Heme titration experiments were then carried out to test whether the Spy49-0662
protein binds heme. Various concentrations of hemin chloride were added to 40 µM of the
purified protein in 20 mM sodium phosphate buffer, pH 7.4. Upon hemin addition, a Soret peak
appeared at 414 nm and increased with incremental addition of hemin. The peak at 414 nm
progressively shifted toward 420 nm and this shift coincided with the appearance of two bands at
530 and 560 nm, consistent with the characteristic spectrum of bound ferrous heme (fig. 16A).
The plot of the differential absorbance at 414 nm as a function of hemin concentration indicated
that the protein bound heme to saturation at 40 µM of hemin, suggesting a 1:1 binding ratio (fig.
16B). On the other hand, the characteristic peaks of bound heme were absent when various
concentrations of hemin were added to the buffer without the protein (fig 16C). Taken together,
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these data established that Spy49-0662 expresses a new heme binding protein in GAS. The
protein was therefore named HupZ (for heme utilization protein). The molar extinction
coefficient for heme-bound HupZ was determined at 414 nm using the pyridine hemochromogen
method and resulted in ε414 nm = 110000 M-1 cm-1 (fig. S19).

Heme degradation by HupZ
Heme degradation by HOs requires a source of reducing equivalent which is provided in
mammals by the combined action of NADPH and cytochrome P450 reductase (CPR) [60,66].
While the native redox partner for the bacterial HOs is mostly unknown, CPR and ascorbic acid
are typically used for in vitro heme degradation studies. HoloHupZ was prepared by mixing the
apoprotein with hemin chloride at a concentration ratio of 1:1.5 (protein to hemin). After 30 min
incubation on ice, the mixture was dialyzed then gel filtered to separate the holoprotein from
excess free heme. Catalase at a final concentration of 2 µM was added to 20 µM holoHupZ in 20
mM sodium phosphate buffer to prevent non enzymatic oxidation of the heme by hydrogen
peroxide. Surprisingly, the Soret peak of the protein, as well as the bands at 530 and 560 nm
decreased over time as the protein solution was incubated at room temperature. This observation
suggested enzymatic heme degradation (fig. 17A). The decrease of the Soret peak and of the
band at 560 nm isosbestically generated growing bands at 360 and 630 nm respectively, showing
the formation and accumulation of an intermediate with maximum absorbance at the
corresponding wavelengths (fig. 17A and inset). As a control, a similar experiment was
conducted using holoShp, another characterized heme-binding protein in GAS. Interestingly, the
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Soret peak as well as the β- and α-bands of holoShp did not decrease over time, indicating that
heme degradation was not taking place (fig. 17B).
We hypothesized that the observed heme degradation by HupZ in presence of catalase
was supported by electrons from a reduced cofactor that might have copurified with the protein.
To test this hypothesis, 2 ml of 20 µM holoHupZ was incubated overnight at 4 °C, with 1 mM of
potassium ferricyanide. Following gel filtration to remove the ferricyanide, the protein was
diluted to 10 µM and catalase was added to it to a final concentration of 2 µM. The UV-visible
absorbance spectrum of the protein solution was subsequently monitored for heme degradation.
Unlike the untreated protein, the Soret peak of the ferricyanide treated holoHupZ did not
significantly decrease, indicating that heme degradation was inhibited by the oxidizing agent
(fig. 17C).

CPR-NADPH as a source of electrons for heme degradation by HupZ
Heme degradation by HupZ was further assessed in a reaction containing 20 µM of the
holoprotein, 2 µM of catalase, 25 µg of CPR and 1 mM of NADPH. The spectral changes of the
reaction were recorded between 350 and 700 nm at room temperature for 1 hour. The peak at 414
nm and the bands at 530 and 560 nm characterizing heme bound to HupZ decreased significantly
in the first 30 min then became stagnant. These variations in the spectral features substantiated
that the bound heme was degraded over time and that the reaction reached it rate-limiting step or
was completed within 30 min. Heme degradation in this reaction was accompanied by a slow
shift of the Soret peak toward 420 nm and generated a growing peak at 670 nm (fig. 18A and
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inset). In addition, the color of the reaction turned from red to green, suggesting biliverdin
production (fig. S20). When the reaction was carried out in the absence of CPR or NADPH, the
spectral changes were similar to that of the holoprotein alone described in fig. 17A (fig. 18B and
18C). An additional control reaction was carried out using a solution containing 20 µM of hemebound NEAT2 (a characterized heme-binding protein in GAS), 2 µM catalase, 25 µg of CPR and
1 mM of NADPH. No changes in the spectral features of the holoprotein were observed after 1
hour (fig. 18D). This clearly, showed that NEAT2 does not degrade heme even in the presence of
the CPR-NADPH system, and that the heme degradation observed in the reaction containing
holoHupZ was imputable to the enzymatic activity of the latter.

Ascorbic acid as reducing partner for HupZ-catalyzed heme degradation
The ability of HupZ to degrade heme using ascorbic acid as an electron donor was tested.
For that, 20 mM of ascorbic acid and 2 µM of catalase were added to 20 µM of holoHupZ and
the absorbance spectra of the reaction were recorded between 350 and 700 nm for one hour. The
spectral variations observed for this reaction did not differ significantly from that of the
holoprotein without addition of a reducing agent (fig. 19A), suggesting that ascorbic acid does
not significantly contribute to HupZ heme oxygenase activity. The addition of ascorbic acid to
holoShp did not change the spectral features of the holoprotein over time (fig. 19B). Here again
the data indicate that the decrease in the characteristic peaks of heme-bound HupZ was catalyzed
by the protein. Unlike with ascorbic acid, an observable reduction of the bound heme iron
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precedes an important decrease of the Soret in presence of CPR-NADPH as a source of
electrons.

Sequence comparison of HupZ and other bacterial heme degrading enzymes
Bacterial HOs are classified in four major groups based on their structural similarities.
Representatives of these different groups include, HmuO from C. diphteriae, IsdG from S.
aureus, ChuS from E. coli and HugZ from H. pylori. To determine whether HupZ belongs to one
of the characterized HOs families, a multiple sequence alignment was conducted using the webbased tool, ClustalW2 (EMBL-EBI). The amino acids sequence of HupZ was aligned against the
sequences of three representatives of each of the four bacterial HOs families. The proteins
members of each family grouped into a single or two linked clades showing their phylogenetic
relatedness as expected (fig. 20). Interestingly, HupZ defines a monophyletic group by itself,
suggesting that it is the prototype of a new family of bacterial HOs (fig. 20). In spite of being
members of different monophyletic groups, HupZ, MhuD and PigA are at similar evolutionary
distance from the root with estimated 43%, 42% and 44% evolution respectively. On the other
hand, the evolutionary distances of the human HO-1 (36%), HmuO (34%) and HugZ (35%) from
the common ancestor are also very similar. HutZ, HmuZ and PhuS evolved between 26 and 30 %
from the common ancestor, whereas IsdG, IsdI, HemS and ChuS were the least evolved with
evolutionary distances between 16 and 18%.
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Discussion 3
During infection, GAS obtain and utilize iron from the mammalian host hemoproteins
[44]. Heme is scavenged from host heme containing proteins by Shr, which subsequently
transfers its heme to Shp. The latter then conveys heme to a dedicated transporter (SiaABC) for
its

transportation

through

the

thick

peptidoglycan

layers

to

the

cytoplasm

[45,53,54,148,152,167]. In the cytoplasm, the imported heme must be degraded through an
enzymatic process to release iron from the porphyrin center [57]. In most bacteria, HOs carry out
this function by catalyzing the oxidative cleavage of the meso carbon bridges of the porphyrin at
the positions α, β, γ or δ [57,59]. In GAS however, the process of heme degradation has not been
reported since homologues of HOs were not found in the genome of these bacteria.
In this study we characterized the protein encoded by hupZ, a gene from GAS that is upregulated in low iron conditions. The protein lacks a secretion signal, indicating its localization
in the cytoplasmic compartment. The recombinant HupZ expressed and purified from E. coli
bound heme to saturation at 1:1 ratio (fig. 16). Thus, it is a novel heme binding protein in GAS
with potentially an intracellular function. We hypothesized that HupZ is involved in heme
metabolism and therefore tested its ability to degrade heme. In vitro heme degradation
experiments require the presence of a suitable reducing equivalent and are typically carried out
with CPR-NADPH or ascorbic acid as electron donors.
Heme bound-HupZ, incubated without the addition of an external reducing partner,
surprisingly degraded heme even in the presence of catalase to prevent non enzymatic oxidation
of heme by hydrogen peroxide (fig. 17). The inherent heme degradation activity of HupZ was

78

inhibited when the protein was incubated with the oxidizing agent, potassium ferricyanide. These
results suggested that HupZ was purified with a reduced cofactor serving as a source of electrons
for heme degradation by the protein. Sequence analysis of HupZ showed that the protein harbors
a PNPOx-like module which is found in FMN-binding proteins. In addition, the cell lysate of E.
coli overexpressing HupZ contained a substantial amount of oxidized FMN that was separated
from the protein during purification (Fig. S18B). Together these observations indicate that the
reduced cofactor that might have purified with HupZ is FMN hydroquinone (FMNH2). The E
coli chorismate synthase, is another example of protein which does not bind oxidized FMN when
purified aerobically but stably binds FMNH2 with high affinity [171,172].
Furthermore, when ascorbic acid was used as an electron source for heme degradation by
HupZ, no difference was observed compared to the activity of the protein by itself. This clearly
indicates that ascorbic acid is not an efficient reducing partner for HupZ function. On the other
hand, heme degradation by HupZ was considerably enhanced when CPR-NADPH was used as
reducing equivalent. The first step of the catalytic mechanism of heme oxygenases is the
reduction of ferric heme to ferrous heme [66]. The spectral shift (from 414 nm to 420 nm)
observed shortly after NADPH addition indicates the formation of ferrous heme, possibly
followed by O2 binding. The reaction produced a green color indicative of biliverdin production,
which was confirmed by the spectral features of the product. In fact, the characteristic peaks of
bound heme progressively decreased while generating isosbestically new peaks that are
consistent with biliverdin absorbance spectrum. Heme degradation by HupZ using its reduced
cofactor or ascorbic acid produced a growing peak at 630 nm while the reaction with CPRNADPH generated a growing peak at 670 nm. This suggests that the products generated by these
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reactions may be different biliverdin isomers, or a mixture of isomers in one case or the other, as
seen with PigA and HugZ [77,92]. Though, further biochemical and chemical analyses are
necessary to unequivocally characterize all the products generated by HupZ catalyzed heme
degradation, as well as its regiospecificity.
Sequence comparison between HupZ and several HOs from different structural families
showed that this enzyme is not related to any previously characterized HO, although it is at
similar evolutionary distance as PigA and HmuD from P. aeruginosa and M. tuberculosis
respectively (fig. 20). A more conclusive structural comparison of HupZ with other HOs will be
carried out in the near future, as the resolution of the protein’s structure by crystallography is
underway.
In conclusion, we identified and characterized for the first time, a heme oxygenase in the
Streptococcus genus which was named HupZ. Orthologs of the protein are found in other
important pathogens such as Streptococcus agalactiae and Streptococcus dysgalactiae. It is the
representative of a new family of flavoenzymes capable of catalyzing heme degradation using
electrons from their reduced flavin cofactor.
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Materials and methods 3
The bacterial strains, media and antibiotics
Escherichia coli (E. coli) cells were grown aerobically in Luria–Bertani (LB) medium at 37 °C
supplemented with 100 µg/ml of ampicillin. The E. coli strains used in this study are listed in
Table 5.

Recombinant HupZ, NEAT2 and Shp proteins
The plasmids and primers used in this study are listed in Tables 5 and 6. The cloning of the
recombinant Shp expressed as a C-terminus fusion to the His-tag was previously described
(Chapter 2). The construction of HupZ-His and NEAT2-His expression vectors was
accomplished by TOPO® directional cloning according to the manufacturer instruction
(Invitrogen, K101-01). The hupZ and shr NEAT2 ORFs were amplified from NZ131
chromosome using the ZE437/ZE438 and ZE427/ZE428 primer sets respectively and introduced
into the pET101/D-TOPO vector. The resulting plasmids, pZZ2 and pOM102, code for a HupZHis tag and NEAT2-His tag fusion proteins respectively, expressed from the T7 RNA
polymerase promoter.
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Proteins expression and purification
Expression of the recombinant His-tagged proteins was induced overnight at 27 °C with 1mM
isopropyl β-D-1-thiogalactopyranoside. Cells were harvested and re-suspended in an extraction
buffer (20 mM Tris pH 8, 100 mM NaCl, 0.1% Triton X-100) with the addition of 0.5 mg/ml and
Complete, mini-EDTA-free protease inhibitor cocktail tablets (Roche), then lysed by sonication.
The cells’ pellet was centrifuged and the cleared lysate was then applied to a 5 ml HisTrap HP
affinity column (nickel column) and purified using a FPLC. Purified proteins were dialyzed in
sodium phosphate buffer (20 mM sodium phosphate, 500 mM NaCl, pH 7.4) prior to their use
for experiments. Western blot analysis of the recombinant His-tagged proteins was carried out
using anti-His antibodies from mouse (Sigma).

Heme reconstitution
The heme reconstitution experiments were conducted as described in [148]. All the spectra were
normalized by sustracting the absorbance at 700 nm.

Heme degradation assays
Heme-HupZ complex was prepared at a hemin:protein ratio of 1.5:1 and excess heme was
removed by filtration through a PD-10 column (GE Healthcare). Degradation of bound heme by
HupZ was carried out without electron donor and with two electron donor systems (ascorbic acid
and NADPH-CPR). Ascorbic acid was added to a final concentration of 20 mM. In the NADPH-
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CPR system, heme-HupZ protein (20 µM) was added to 25 μg of recombinant human NADPHcytochrome P450 reductase (CPR). The reaction was initiated by adding NADPH to 1 mM and
spectra were recorded from 350 nm to 700 nm every 10 min for 1 h. Catalase (bovine liver,
Sigma-Aldrich) was added to the reaction systems at a final concentration of 2 μM. All reaction
systems were in 1 ml total volume.
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Table 5: Strains and Plasmids used in this study
Name

Description

Source/Reference

E.coli Top10

Host for pOM101 and pZZ2 propagation

Invitrogen

E.coli BL21 Star

Host for pOM101 and pZZ2 expression

Invitrogen

pOM102

Expresses NEAT2-His tag from PT7

This study

pET101/D-TOPO

Directional TOPO® TA cloning vector

Invitrogen

pOM101

Expresses Shp-His tag from PT7

Chapter 2

pZZ2

Expresses HupZ-His tag from PT7

This study

Strains

Plasmids

Table 6: Primers used in this study

Name

Sequence

Description

ZE427

ATGAATCAAAAACAATTGCGTG

Sense primer for Shr NEAT2 domain

ZE428

AACCTTTGCCTTCTCTGTTGTAAGG

Anti-sense primer for Shr NEAT2 domain

ZE437

ATGATAACACAAGAAATGAAA

Sense primer for hupZ

ZE438

GTTACTTTCACTGTTTATTTCTT

Anti-sense primer for hupZ
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GENERAL DISCUSSION

The novel Hb binding motif in Shr NTD
Hb binding is the first and probably the most important step in the process of heme
uptake. It is mediated in the vast majority of Gram-negative bacteria by a consensus protein
motif FRAP/NPNL [1] and by a NEAT domain in most Gram-positive hemoproteins receptors
[2-6]. Interestingly, the two NEAT domains of Shr do not participate in Hb binding by the
protein; rather, this function is carried out by an uncharacterized region of Shr NTD. The Hb
binding NEAT domains of Staphylococcus aureus IsdH and IsdB contain an aromatic motif
consisting of YYHY or YYHFF [2]. These aromatic motifs as well as the consensus motif found
in Gram-negatives are absent from Shr NTD, suggesting that the latter contains a novel
alternative Hb binding motif, which is yet to be identified and characterized [7]. On the other
hand, NTD contains two copies of a domain of unknown function (DUF1533) that can be
legitimately hypothesized as the possible Hb binding domains of Shr.
One possibility for identifying the precise region and amino acid residues required for Hb
binding by Shr is to conduct partial deletions in order to determine the minimal NTD sequence
capable of carrying the function. Subsequently, site directed mutagenesis targeting various
residues may be employed to identify a critical motif. Alternatively, a DNA library from Shr
NTD’s sequence may be used to achieve a phage display, which will allow for the selection of
NTD subdomains that show Hb binding. A successful identification of this novel Hb binding
motif may also serve as the basis for identifying and studying the function of other bacterial
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proteins in which it can be found. Moreover, an emerging strategy to counter bacterial adaptation
to antibiotics is the development of molecules that target the iron metabolism of bacteria. One
approach is the use of chelators and antagonists to inhibit the binding of iron or iron complexes
such as Hb to their receptors [8]. The kinetic studies herein, demonstrate that Shr must bind Hb
to efficiently scavenge heme from it. Therefore, the Hb binding motif in Shr constitutes a good
target for the development of novel therapeutic molecules against GAS.

Significance of heme reduction by Shr
Shr is copurified with a mixture of ferric and ferrous heme and has the capacity to acquire
and reduce ferric heme from solution [7,9]. On the other hand, isolated NEAT2 contains mostly
ferrous heme whereas NEAT1 domain is purified with ferric heme. The data from the kinetic
studies of heme transfer show that heme is passed from metHb to both NEAT1 and NEAT2
domains in a direct process, but only NEAT1 efficiently transfers its heme to Shp. This observed
functional difference may relate to the oxidation status of the heme iron. Examples that support
this hypothesis and where the redox state of the iron in bound heme affects the properties of the
hemprotein were reported. In IsdC NEAT domain, the reduction of ferric heme causes heme loss
by the protein [10]. In addition, the iron axial ligand of IsdA switches from tyrosine to histidine
when the ferric heme is reduced. A mechanism of closing/opening of the heme binding pocket,
depending on the oxidative state of the heme iron, was therefore suggested for IsdA [10,11].
Moreover, porphyrin with a ferric center binds with higher affinity and stability to IsdH NEAT3
than porphyrin a ferrous center [12].
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In the Shr heme reconstitution assay, ferric heme reduction by the protein was more
pronounced with increasing amounts of bound heme, suggesting that excess of heme may favor
the process. It is therefore plausible to hypothesize that in high heme conditions, NEAT2 binds
and reduces ferric heme for storage in the ferrous form, and in low heme situations ferric heme is
regenerated then passed to NEAT1 for export to Shp. The storage of ferrous heme which is
supposedly less stable and weakly bound is probably rendered possible by the association of
ferrous heme with gaseous ligands such as O2, CO or NO in the context of the host environment
[13,14]. This hypothesis can be tested by conducting comparative kinetic studies of heme
transfer using stopped-flow spectrophotometer in both aerobic and anaerobic conditions. Rates
comparisons between reactions using fully reduced and fully oxidized proteins, as well as
between aerobic and anaerobic transfer reactions, will provide direct evidence of the importance
for maintaining a certain redox status to achieve an efficient heme transfer.

Basis for the heme degradation by HupZ alone
We identified for the first streptococcal HO (HupZ), which does not relate in sequence
and in mechanism to any previously studied HO. HoloHupZ is capable of degrading its bound
heme without externally supplied reducing partner. This inherent HO activity is inhibited when
the protein is treated with potassium ferricyanide. These observations suggest that HupZ is
copurified with a reduced cofactor serving as the electrons donor for heme degradation. In silico
analysis of HupZ, shows that the protein contains a module from the superfamily of the signature
domain of the pyridoxamine 5'-phosphate oxidase (PNPOx). The latter is a FMN flavoprotein
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that catalyzes the oxidation of pyridoxamine-5-P (PMP) and pyridoxine-5-P (PNP) to pyridoxal5-P (PLP). In addition to the presence of a PNPOx domain in HupZ, cell lysate of E. coli
overexpressing the protein displays a yellow color that is retained in the affinity column during
purification. However, the yellow substance is eluted out of the column in a fraction, which is
protein-free and separate from that of HupZ. UV-visible spectroscopic analysis shows that the
absorbance spectrum of the yellow fraction is consistent with the absorbance spectrum of FMN.
A similar situation is seen with E coli chorismate synthase, which does not bind oxidized
FMN when purified aerobically [15]. Addition of chorismate synthase to oxidized FMN solution
did not quench the fluorescence of the cofactor and ultracentrifugation recovered almost all of
the FMN in the filtrate [16]. This underlines the weak binding of oxidized FMN to chorismate
synthase and is consistent with the fact that the flavin cofactor is entirely loss during purification
[15,16]. The purified chorismate synthase, whose activity requires the reduced form of the flavin
cofactor FMNH2, is fully functional in the presence of FMNH2 and dithionite. This suggests that
in spite of its inability to associate with oxidized FMN, the protein binds FMNH2, the reduced
form of the flavin cofactor and its binding affinity was determined to be more than ten times
higher than the estimated affinity for oxidized FMN binding [15,16]. On the other hand, the
binding affinity of oxidized FMN to chorismate synthase was increased in the presence of the
substrate and analogs of the substrate [17].
It seems possible that like chorismate synthase, HupZ is an FMN binding protein with
high affinity to the reduced form of the cofactor. Isolation with some reduced FMN may also
explain the heme degradation in the absence of external reducing agent. This hypothesis can be
tested by several means. First, as done by Macheroux et al [16], the reduction of FMN and the
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binding of the reduced cofactor by HupZ can be simultaneously followed in anaerobiosis, by
monitoring the UV-visible spectrum of FMN in presence of HupZ and the xanthine/xanthineoxidase couple as a reducing partner. Second, the kinetics of inherent heme degradation by
HupZ alone, and by HupZ in the presence of dithionite and FMN can be conducted in a stoppedflow spectrophotometer to assess whether reduced FMN increases the rate of heme degradation.
In the same experiments, the formation of the flavin-quinone intermediates characterizing
passage from one oxidative state to another can be monitored and correlated with heme
degradation. Finally, resolving the crystal structure of HupZ in the presence and in the absence
of FMN will reveal the presence or not of the reduced flavin cofactor.

Potential in vivo reducing partners of HupZ
The catalytic action of HOs requires reducing equivalents that are provided in mammals
by CPR-NADPH [18,19]. CPR is a flavoprotein that contains one FAD and one FMN prosthetic
groups. In plants, cyanobacteria and some eubacteria, the redox system composed of NADPH,
ferredoxin reductase (FNR) and ferredoxin is suggested to be the reducing partner of the HOs
[20-22]. A recent study showed that pa-HO (PigA), a HO from P. aeruginosa can efficiently
degrade heme using FNR, a FAD-containing flavoprotein, as a reducing partner without the
requirement for ferredoxin [23]. Though, additional FNR mediated heme oxygenation has not
been shown for any other bacterial system and may not represent the general mechanism for
bacteria.
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Studies associating flavins with the catalytic mechanisms of HOs are on the rise. Like
HupZ, several bacterial HOs were recently described as potentially FMN-binding proteins
[24,25]. FMN-containing heme enzymes such as flavocytochrome b2 have been extensively
studied and have been shown to oxygenate the heme substrate using electrons from the flavin
hydroquinone (FMNH2) [26]. This suggests that the reduced cofactor by itself may be sufficient
to sustain heme degradation by this class of enzymes in vivo. However, because of the lack of
experimental evidence so far for FMN binding by these HOs, it cannot be ruled out that HupZ
may rely on an intracellular reducing partner to carry out its catalytic activity. Therefore, several
approaches can be used to identify possible reducing partners of HupZ. One perspective is to
conduct genome mining for flavin-dependent oxidases/reductases in GAS and express the
recombinant proteins for characterization. Another possibility is to perform a cross-linking in
GAS cell lysate followed by immunoprecipitation. Alternatively, purified HupZ may be
incubated with GAS cell lysate to allow for possible complex formation. Subsequent separation
of the complex from the lysate may allow fishing out and identifying a putative HupZ partner
protein.

HupZ heme degradation products
Heme degradation by the conical HO produces CO, α-biliverdin and free iron [27].
However, several bacterial HOs that generate unconventional products were reported. For
example, along with CO and free iron, IsdG catalyzes heme degradation to produce an oxobilirubin (staphylobilin), whereas PigA and HugZ generate β- and δ-biliverdins [28-30]. On the
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other hand, the products of heme degradation by HupZ are yet to be characterized. The
spectroscopic analysis of the heme catabolism reactions showed that the decrease of the Soret
peak and of the α- and β-bands is accompanied by a concomitant increase around 360 nm and
630 nm respectively. These spectral features are different from those of all the HOs mentioned
above and suggest that the product generated may be an unprecedented isomer of biliverdin
(such as γ-biliverdin) or a mixture of isomers. Furthermore, the reaction of heme degradation by
HupZ using CPR-NADPH as electrons donor turns from red to green after one hour of
incubation, consistent with the production of biliverdin.
Further studies to characterize and unequivocally identify the products generated by
HupZ-catalyzed heme degradation are underway. For that, the final product will be extracted
with organic solvents then lyophilized in order to concentrate the products in a minimal volume.
Additional purification steps will be applied as needed prior to separation of the products by
HPLC. UV-visible spectroscopy and mass spectrometry will be conducted on the samples
collected from the HPLC separation. More analyses such as NMR or ENDOR (Electron-Nuclear
Double Resonance) spectroscopy may be necessary to determine the chemical structures of the
products.
In mammals, biliverdin produced by HO-catalyzed heme degradation is reduced into
bilirubin by a biliverdin-reductase (BVR) [31]. The fate of the biliverdin in bacteria is unknown
in most cases. A homologue of mammalian biliverdin reductase has been identified only in
cyanobacteria [32,33]. In Pseudomonas aeruginosa, a bacterial phytochrome BphP, removes
biliverdin from the catalytic site of PigA and BphO. However, a subsequent transformation of
the removed biliverdin by BphP was not shown and its physiological relevance is still unclear
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[22]. Therefore, the fate of biliverdin in non-photosynthetic bacteria remains an intriguing
question which constitutes the focus of several ongoing investigations.
It is conceivable that, like in Pseudomonas aeruginosa, a dedicated protein in GAS
removes the bound biliverdin from HupZ active site and eventually delivers it to a putative
enzyme for further conversion. Alternatively, a single protein may carry out the dual function of
biliverdin removal and transformation, in which case it would mechanistically resemble the
mammalian BVR. Strategies like those suggested in the section above may be adopted to look
for proteins involved in biliverdin conversion or excretion from the cell.

In summary, this study explored the role of Shr in heme acquisition by GAS and
established the protein as a new type of composite NEAT-containing receptor. It also deciphered
the molecular mechanism of heme scavenging and transfer by Shr from metHb, providing the
first example of intra-molecular heme exchange between NEAT domains. In addition, this work
solved a long-standing enigma by identifying and characterizing for the first time a heme
oxygenase in the Streptococcus genus (HupZ). Importantly, this study provided new direct
evidence that associates flavins with heme metabolism in bacteria, thus setting a new direction in
the field of heme acquisition and utilization by pathogens.
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Figure 1: (A) Schematic representation of the sia operon and the Shr protein. (B) Heme
relay in Group A Streptococcus.
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Figure 2: Catalytic mechanism of heme oxygenases [1].

94

Figure 3:
3 Shr proteeins in pyog
genic Strepttococci and Clostridium
m novyi. LP: Leader Pepptide;
DUF: Do
omain of Unknown
U
Fun
nction 1533
3; NEAT: N
NEAr Transpporter domaain; EF: EF--hand
motif; TM
M: TransMembrane dom
main.

95

Figure 4: Hemin binding and reduction by rShr. (A) SDS-PAGE showing purified rShr. (B) 9
μM Shr (blue line) was treated with 10 mM of DTT (red line) or 30 μM ferricyanide (FCN)
(green line). Histag elution buffer containing 10 mM DTT was used as a blank for DTT-treated
Shr spectrum and excess ferricyanide was removed from the protein sample by dialysis in
phosphate buffer. (C) An increase of heme bound to Shr (3 μM) as increasing concentrations (1
μM, red; 3 μM, green; 5 μM, purple; 10 μM, blue; or 20 μM, orange) of hemin were added to

96

the protein is shown by the sharp peak at 414 nm. Hemin reduction is indicated by the growing
absorbance at 427 nm and at ~540 and ~564 nm. The corresponding hemin chloride
concentrations in Histag elution buffer served as blanks for the UV-visible scans (see figure S2).
The insert magnifies the 500 nm – 700 nm region. (D) UV-visible spectra of rShr following the
addition of 20 μM hemin (red line) and treatment with ferricyanide (blue line). Hemin reduction
shown by the presence of a Soret peak at 427 nm and by the peaks at ~540 and ~564 nm (red
spectrum) is reversed by the addition of ferricyanide (blue spectrum).
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Figure 5: Heme binding by Shr fragments. (A) Schematic representation of NTD, NTD-N1
and NEAT2. LP: Leader Peptide; ST: Strep-Tag; DUF: Domain of Unknown Function 1533;
NEAT: NEAr Transporter domain; (B) SDS-PAGE showing purified recombinant Shr fragments
(1) Molecular weight marker, (2) NEAT2, (3) NTD, (4) NTD-N1. The UV-visible spectra of
NEAT1 (C), NTD (D), NTD with additions of hemin chloride (1 μM, red; 5 μM, green; or 10
μM, purple) (E) and NEAT2 (F). (G) UV-visible spectra of NEAT2 following titration with 20
μM hemin (blue). The red and green lines, respectively, represent the spectrum 5 min and 24 h,
after addition of 6 μM ferricyanide. The insert magnifies the 400 nm – 460 nm region, showing
the shifts in the Soret peaks. The Strep-tag wash buffer alone was treated exactly the same way
as the protein solution, and used as blank for UV-visible scan.
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Figure 6: (A) Methemoglobin binding by Shr fragments. ELISA showed methemoglobin
binding by rShr (crosses), NTD (black squares), and NTD-N1 (triangles). In contrast, NEAT2
(dots) or BSA (diamonds) did not bind methemoglobin. ELISA testing apohemoglobin binding
by NTD (Red squares) showed no binding. The plates were coated with rShr or the Shr
fragments and subsequently reacted with increasing concentrations of methemoglobin or
apohemoglobin. Protein binding was detected with anti-hemoglobin antibodies as described in
Materials and Methods. (B) Direct detection of immobilized holohemoglobin (triangles) and
apohemoglobin (squares) with anti-hemoglobin antibodies. Uncoated wells (diamonds) were
used as a negative control. Each datum point in sections A and B represents the mean ± SD
(represented by the error bars) from data from at least two independent experiments done in
triplicates.
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Figure 7: Binding of extracellular matrix proteins by Shr. Elisa assay showing fibronectin
(A) and laminin (B) binding by rShr (crosses) and NEAT2 (dots). NTD-N1 (triangles) slightly
bound fibronectin but did not bind laminin. In contrast, NTD (squares) or BSA (diamonds) did
not bind fibronectin or laminin. The plates were coated with rShr or Shr fragments and
subsequently reacted with increasing concentrations of fibronectin or laminin as described in
Materials and Methods. Each datum point in panels A and B stands for the mean ± SD (shown
by the error bars) of three independent experiments done in triplicates.
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Figure 8: Heme transfer from methemoglobin to apoNTD-N1. (A) UV-visible spectra of 10
μM apoNTD-N1 after contact with methemoglobin (red) or hemin chloride (blue) and 10 μM
apoNTD-N1 (green). (B) Western blot analysis of the fraction containing the Hb washes and
NTD-N1 elution. Proteins (50 ng/well) were detected with anti-Hb (upper panel) or anti-Shr
(lower panel) antibodies. (1) MW Marker; (2) purified apoNTD-N1; (3) Hb fraction; (4) NTDN1 after Hb flow; (5) Empty lane; (6) Hb 50 ng ; (7) Hb 100 ng.
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Figure 9: Growth analysis of shr deletion mutants. (A) Schematic representation of the in
frame deletions created in Shr. WT: wild type; ΔNEAT1: a deletion of the NEAT1 domain;
ΔNEAT2: a deletion of the NEAT2 domain; ΔNEAT1-2: a deletion of both NEAT1 and
NEAT2 domains. Panels B-E describe the characterization of the constructed GAS mutants (B)
The first panel shows PCR analysis of the chromosomal shr gene. Total RNA from each strain is
shown in the second panel. The third and fourth panels respectively show RT-PCR analysis of
the expression of shr (ZE106/126 primers) and siaA (204A-Fwd/Rev primers) genes. (C)
Western blot showing the expression of the corresponding Shr protein variants. WT: wild type
GAS (strain NZ131); ΔN1: NEAT1 mutant (strain ZE4925); ΔN2: NEAT2 mutant (strain
ZE4926); ΔN1N2: NEAT1-2 mutant (strain ZE4929); Shr::spec: non polar null shr mutant
(strain ZE4912); ΔN1N2/pXL14: NEAT1-2 mutant complemented with shr (strain ZE4924). A 1
ml volume of each culture at OD600 = 1 was processed and 20 μl of the prepared samples were
loaded per well. (D) Growth in CDM in the presence of 20 μM of iron. (E) Growth in CDM with
2 mM dipyridyl and no additional source of iron. (F) Growth in CDM with 2 mM dipyridyl and
20 μM of methemoglobin, as the sole source of iron. Diamonds: wild type GAS (strain NZ131);
Squares: ΔNEAT1 mutant (strain ZE4925); Triangles: ΔNEAT2 mutant; Crosses: ΔNEAT1-2
mutant; Dots: null shr mutant. (G) Growth of wild type and Shr complemented strains in CDM
with 2 mM dipyridyl and 20 μM of hemoglobin as the sole source of iron. Diamonds: wild type
GAS; Crosses: ΔNEAT1-2 mutant complemented with shr; Dots: Null shr mutant (shr::aad9)
complemented with shr (strain ZE4924). Cells were grown in a 96 well microplate at 37 °C for
24 h and growth was monitored at OD600. Each datum point in all of the panels represents the
mean of at least two independent experiments performed in triplicates. For clarity purpose the
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SD (represented by the error bars) is shown only in panel F (in which significant growth
differences are found between the strains).

Figure 10: Heme acquisition from MetHb. (A) UV-visible absorbance spectra of apoNEAT1
before (dashed line) and after incubation with metHb (smooth line). The Soret peak at 412 nm
indicates ferric heme binding by NEAT1. (B) UV-visible absorbance spectra of apoNEAT2
(dashed line) and apoNEAT2 after incubation with metHb (smooth line). A major Soret peak at
426 nm along with peaks at 410 nm, 530 and 560 nm indicate a mixture of bound ferric and
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ferrous heme. All the absorbance spectra were corrected by subtracting their corresponding
background absorbance at 700 nm.

Figure 11: Kinetics of heme transfer from metHb to apoNTD-N1. (A) Traces of the
absorbance at 414 nm of the reaction containing 2.5 μM of apoNTD-N1 and various
concentrations of metHb recorded as a function of time. Absorbance variations at 414 nm as a
function of time best fitted a triple exponential at all concentrations of metHb tested (equation 2).
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(B) Observed rate constants for the first phase of heme transfer from metHb to apoNTD-N1
plotted as a function of metHb concentration and fitted using the equation: kobs1 = k1 + k2 * (Keq /
(Keq + x)) (R2 = 0.99). (C) The observed rate constants for the second (kobs2) and third (kobs3)
phases as functions of metHb concentration. All concentrations of metHb were based on heme
bound absorption.

Figure 12: Kinetics of heme transfer from metHb to the full-length Shr. (A) Traces of the
absorbance at 414 nm of the reaction containing 2.5 μM of apoShr and various concentrations of
metHb recorded as a function of time. Absorbance variations at 414 nm as a function of time best
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fitted a triple exponential at all concentrations of metHb tested (equation 2). (B) Observed rate
constants for the first phase of heme transfer from metHb to apoShr plotted as a function of
metHb concentration. kobs1 was fitted using the equation: kobs1 = 1+[6.5x / (12 + x)] (R2 = 0.99).
(C) The observed rate constants for the second (kobs2) phase were fitted using the equations: kobs2
= 2.3x / (138 + x) (R2 = 0.99).

Figure 13: Kinetics of heme transfer from Shr NEAT domains to apoShp. Various
concentrations of holoNEAT1 or holoNEAT2 were mixed with apoShp (2.5 μM). (A)
Representative trace of the time course of heme transfer from holoNEAT1 to apoShp. (B) The
observed rate constants for the fast phase of heme transfer from holoNEAT1 to apoShp plotted
as a function of [holoNEAT1] was fitted using the equation: y = 2.5x (R2 = 0.99). (C) The
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observed rate constants for the slow phase of heme transfer from holoNEAT1 to apoShp plotted
as a function of [holoNEAT1] was fitted using the equation: y = 0.017x. (R2 = 0.89). (D)
Representative trace of the time course of heme transfer from holoNEAT2 to apoShp. (E) The
plot of the observed rate constants of the heme transfer from holoNEAT2 to apoShp as a function
of [holoNEAT2] fitted using the equation: y = 0.01x / (x+25). (R2 = 0.99)
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Figure 14: Heme transfer from holoNEAT1 to apoNEAT2. (A) UV-visible absorbance
spectra of apoNEAT2 before (dashed line) and after incubation with holoNEAT1 (smooth line).
ApoNEAT2 upon incubation with holoNEAT1 showed Soret peaks at 411 and 426 nm as well as
peaks at 530 and 560 nm, indicating a mixture of bound ferric and ferrous heme. (B) Kinetics of
heme transfer from holoNEAT1 to apoNEAT2. The observed rate constants plotted as a function
of [holoNEAT1] increased in [holoNEAT1]-dependent manner and was fitted using the
equation: y = 0.14x (R2 = 0.94).

Figure 15: Proposed model of heme acquisition by the S. pyogenes Sia system. Shr binds
metHb through NTD and forms an intermediate protein complex, which may facilitate direct
heme transfer from metHb to NEAT1 and NEAT2 and eventually the release of heme from
metHb in solution. Heme scavenged by NEAT1 is rapidly transferred to Shp for delivery into the
cell by the SiaABC transporter. Heme acquired by NEAT2 is stored and transferred back to
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NEAT1 when needed, possibly when heme availability is limiting. The full and dashed arrows
indicate the heme flow under low and high heme availability, respectively.

Figure 16: Heme binding by HupZ. Various concentrations of hemin chloride were added to
40 µM HupZ in 1 ml of 20 mM sodium phosphate buffer. The corresponding hemin
concentrations in 1 ml of the buffer without protein were used as blanks (A). The differential
absorbance at 414 nm plotted as a function of [hemin] shows a binding stoichiometry of 1:1 (B).
The spectra of free heme in the buffer (C), showing major differences with those of bound heme
seen in (A).
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Figure 17: Heme degradation by HupZ without external electron donors. (A) HupZcatalyzed heme degradation in absence of exogenous reducing equivalent. The inset magnifies
the region between 500 and 700 nm showing the decrease of the bands at 530 and 560 nm and
the concomitant increase of a band at 630 nm. The arrows indicate the direction of the changes.
(B) The spectral features of heme bound to Shp did not change over time, indicating absence of
heme degradation. (C) Inhibition of HupZ catalytic activity by potassium ferricyanide.
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Figure 18: heme degradation by HupZ using CPR-NADPH as reducing equivalent. (A)
Heme degradation with CPR-NADPH as source of electrons. The inset magnifies the region
between 500 and 700 nm showing the decrease of the bands at 530 and 560 nm and the
concomitant increase of a band at 670 nm. The arrows indicate the direction of the changes. The
reaction in absence of CPR (B) or NADPH (C) did not enhance heme degradation by HupZ. (D)
Control reaction carried out with heme bound NEAT2 and the CPR-NADPH system.
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Figure 19: heme degradation by HupZ with ascorbic acid as a source of electrons. (A)
Heme degradation by HupZ using ascorbic as a reducing partner. The inset magnifies the region
between 500 and 700 nm showing the decrease of the bands at 530 and 560 nm and the
concomitant increase of a band at 630 nm. The arrows indicate the direction of the changes. (B)
Control reaction carried out with heme bound Shp and ascorbic acid.

Figure 20: Phylogenetic tree of bacterial heme oxygenases generated from ClustalW2
(EMBL-EBI). The number displayed for each HO represents its evolutionary distance from the
root.
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Figure S1: NEAT alignment. Sequence alignment of the heme-binding NEAT domains of
IsdA, IsdH, IsdB, IsdC, and the two NEAT domains of GAS Shr. Alignment was generated
using the ClustalW program. Important residues found in the heme-binding pocket are indicated
by the black frames [2]. The residues corresponding to K75 and S82 of IsdA heme binding
pocket are conserved in Shr NEAT1 and NEAT2. The conserved iron-coordinating Y166 in Isd,
however, is absent from Shr NEAT domains and the Isd-conserved Y170 is present in Shr
NEAT1 only. The aromatic residues at position 87 and 113 are present in Isd but not in Shr.
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Figure S2: UV-visible spectra of hemin chloride. Increasing concentrations of hemin chloride
were added to Histag elution buffer and the spectra were determined as described in Material and
methods.

Figure S3: Heme reconstitution of NEAT2 protein fragment. Increasing concentrations (1
μM, red; 3 μM, green; 5 μM, purple; 10 μM, light blue and 20 μM, orange) of hemin chloride
were added to NEAT2 protein in Strep-tag elution buffer. The corresponding hemin chloride
concentrations were added to Strep-tag elution buffer and used as blanks for the UV-visible
scans.
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Figure S4: Binding of rShr to holo and apo hemoglobin. Binding of rShr to microtiter plate
wells coated with 200 nM Goat IgG (circles), 200 nM apohemoglobin (squares), and 200 nM
holohemoglobin (triangles). Increasing concentrations of rShr were incubated in wells overnight
at 4 ºC. Bound protein was detected with polyclonal anti-Shr antibodies and anti-rabbit AP
conjugated antibodies. The experiments were repeated twice and the values are derived from the
means of triplicate wells.
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Figure S5: Heme transfer from methemoglobin to apoNTD-N1. UV-visible spectra of
apoNTD-N1 (black), apoNTD-N1 after 5 min incubation with methemoglobin (blue) and
apoNTD-N1 after 75 min incubation with methemoglobin (red). ApoNTD-N1 (100 nmoles in 2
ml Strep-tag wash buffer) was incubated with methemoglobin (50 nmoles in phosphate buffer
solution). NTD-N1 was separated from methemoglobin through a Strep-Tactin column following
an extensive wash with Strep-tag wash buffer.
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Figure S6: Growth phenotype of wild type GAS and Shr mutants. (A) In presence of 2 mM
dipyridyl and 5 μM of human hemoglobin as sole source of iron. (B) In presence of 2 mM
dipyridyl and 10 μM of human hemoglobin as sole source of iron. (C) In presence of 2 mM
dipyridyl and 60 μM of human hemoglobin as sole source of iron. Cells were grown in a 96 well
microplate at 37 °C for 24 h and the growth was monitored at OD600. Diamonds: wild type GAS;
Crosses: ΔNEAT1-2 mutant (strain ZE4929); Dots: non polar null shr mutant (shr::aad9, strain
ZE4912). The vertical bars indicate the standard deviation between triplicates of two repeated
experiments.
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Figure S8:
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Figure S11:
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Figure S12:
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Figure S13: Spectral differences between metHb and NTD-metHb complex. (A) UV-visible
spectra of metHb and NTD-metHb, MBP-metHb mixtures. (B) UV-visible spectrum of 4.5 μM
NTD.
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Figure S14:
S
Gel filtrration elutio
on profiles of
o NTD-N1 (A) and ald
dolase (B).
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Figure S15:
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Figure S16:
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Figure S17:
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Figure S18: characterization of the purified recombinant HupZ. SDS-PAGE of HupZ
elution fractions shows single bands consistent with the expected size of the protein (A). UVvisible absorbance spectra of the yellow eluate showing the characteristic features of oxidized
FMN (B) and of HupZ as purified (C). The insets show an enlarged scale of the 300-700 nm and
300-600 nm regions, respectively.
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Figure S19: UV-visible absorbance spectra of heme bound HupZ and of the heme-pyridine
adduct.

Figure S20: Characteristic color of HupZ-CPR-NADPH heme degradation reaction. The
starting color (A) and the ending color (B) of the reaction showing the change from red to green.
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Scheme 1: proposed kinetic model of heme transfer from metHb to apoNTD-N1

Scheme 2: proposed kinetic model of heme transfer from metHb to apoShr
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Scheme 3: First and second phases of heme transfer from holoNEAT1 to apoShp
HoloNEAT1* and apoNEAT1* represent alternative species of holoNEAT1 and apoNEAT1,
respectively.
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